BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740-748. [PMID: 26657899 DOI: 10.1136/gutjnl-2015-310376] [Cited by in Crossref: 467] [Cited by in F6Publishing: 425] [Article Influence: 66.7] [Reference Citation Analysis]
Number Citing Articles
1 Dam G, Vilstrup H, Andersen PK, Bossen L, Watson H, Jepsen P. Effect of proton pump inhibitors on the risk and prognosis of infections in patients with cirrhosis and ascites. Liver Int 2019;39:514-21. [DOI: 10.1111/liv.14012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
2 Lucena MI, Sanabria J, García-cortes M, Stephens C, Andrade RJ. Drug-induced liver injury in older people. The Lancet Gastroenterology & Hepatology 2020;5:862-74. [DOI: 10.1016/s2468-1253(20)30006-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
3 Gaiser RA, Halimi A, Alkharaan H, Lu L, Davanian H, Healy K, Hugerth LW, Ateeb Z, Valente R, Fernández Moro C, Del Chiaro M, Sällberg Chen M. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut 2019;68:2186-94. [PMID: 30872392 DOI: 10.1136/gutjnl-2018-317458] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 18.3] [Reference Citation Analysis]
4 Drew DA, Chan AT. Aspirin in the Prevention of Colorectal Neoplasia. Annu Rev Med 2021;72:415-30. [PMID: 33035431 DOI: 10.1146/annurev-med-060319-120913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
5 Hayden HS, Eng A, Pope CE, Brittnacher MJ, Vo AT, Weiss EJ, Hager KR, Martin BD, Leung DH, Heltshe SL, Borenstein E, Miller SI, Hoffman LR. Fecal dysbiosis in infants with cystic fibrosis is associated with early linear growth failure. Nat Med 2020;26:215-21. [PMID: 31959989 DOI: 10.1038/s41591-019-0714-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
6 Rodrigues FG, Ormanji MS, Heilberg IP, Bakker SJL, de Borst MH. Interplay between gut microbiota, bone health and vascular calcification in chronic kidney disease. Eur J Clin Invest 2021;51:e13588. [PMID: 33948936 DOI: 10.1111/eci.13588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Di Tommaso N, Gasbarrini A, Ponziani FR. Intestinal Barrier in Human Health and Disease. Int J Environ Res Public Health 2021;18:12836. [PMID: 34886561 DOI: 10.3390/ijerph182312836] [Reference Citation Analysis]
8 Anhê FF, Varin TV, Schertzer JD, Marette A. The Gut Microbiota as a Mediator of Metabolic Benefits after Bariatric Surgery. Canadian Journal of Diabetes 2017;41:439-47. [DOI: 10.1016/j.jcjd.2017.02.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 8.6] [Reference Citation Analysis]
9 Tyakht AV, Manolov AI, Kanygina AV, Ischenko DS, Kovarsky BA, Popenko AS, Pavlenko AV, Elizarova AV, Rakitina DV, Baikova JP, Ladygina VG, Kostryukova ES, Karpova IY, Semashko TA, Larin AK, Grigoryeva TV, Sinyagina MN, Malanin SY, Shcherbakov PL, Kharitonova AY, Khalif IL, Shapina MV, Maev IV, Andreev DN, Belousova EA, Buzunova YM, Alexeev DG, Govorun VM. Genetic diversity of Escherichia coli in gut microbiota of patients with Crohn's disease discovered using metagenomic and genomic analyses. BMC Genomics 2018;19:968. [PMID: 30587114 DOI: 10.1186/s12864-018-5306-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
10 Katsimichas T, Antonopoulos AS, Katsimichas A, Ohtani T, Sakata Y, Tousoulis D. The intestinal microbiota and cardiovascular disease. Cardiovascular Research 2019;115:1471-86. [DOI: 10.1093/cvr/cvz135] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
11 Douwes RM, Gomes-Neto AW, Eisenga MF, Vinke JSJ, de Borst MH, van den Berg E, Berger SP, Touw DJ, Hak E, Blokzijl H, Navis G, Bakker SJL. Chronic Use of Proton-Pump Inhibitors and Iron Status in Renal Transplant Recipients. J Clin Med 2019;8:E1382. [PMID: 31484461 DOI: 10.3390/jcm8091382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
12 Wauters L, Slaets H, De Paepe K, Ceulemans M, Wetzels S, Geboers K, Toth J, Thys W, Dybajlo R, Walgraeve D, Biessen E, Verbeke K, Tack J, Van de Wiele T, Hellings N, Vanuytsel T. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021:S2468-1253(21)00226-0. [PMID: 34358486 DOI: 10.1016/S2468-1253(21)00226-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mailhe M, Ricaboni D, Vitton V, Gonzalez JM, Bachar D, Dubourg G, Cadoret F, Robert C, Delerce J, Levasseur A, Fournier PE, Angelakis E, Lagier JC, Raoult D. Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing. BMC Microbiol 2018;18:157. [PMID: 30355340 DOI: 10.1186/s12866-018-1304-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
14 Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:389-400. [PMID: 28653751 DOI: 10.1111/apt.14203] [Cited by in Crossref: 170] [Cited by in F6Publishing: 148] [Article Influence: 34.0] [Reference Citation Analysis]
15 Jung HK, Talley NJ. Role of the Duodenum in the Pathogenesis of Functional Dyspepsia: A Paradigm Shift. J Neurogastroenterol Motil. 2018;24:345-354. [PMID: 29791992 DOI: 10.5056/jnm18060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 5.8] [Reference Citation Analysis]
16 Zhu J, Qi X, Yu H, Yoshida EM, Mendez-Sanchez N, Zhang X, Wang R, Deng H, Li J, Han D, Guo X. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. United European Gastroenterol J. 2018;6:1179-1187. [PMID: 30288280 DOI: 10.1177/2050640618773564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
17 Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med 2017;177:784-91. [PMID: 28346595 DOI: 10.1001/jamainternmed.2017.0212] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 14.6] [Reference Citation Analysis]
18 Coman V, Vodnar DC. Gut microbiota and old age: Modulating factors and interventions for healthy longevity. Exp Gerontol 2020;141:111095. [PMID: 32979504 DOI: 10.1016/j.exger.2020.111095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
19 Spanogiannopoulos P, Turnbaugh PJ. Broad collateral damage of drugs against the gut microbiome. Nat Rev Gastroenterol Hepatol 2018;15:457-8. [PMID: 29752457 DOI: 10.1038/s41575-018-0028-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
20 Castellani C, Singer G, Kashofer K, Huber-Zeyringer A, Flucher C, Kaiser M, Till H. The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study. Front Cell Infect Microbiol. 2017;7:444. [PMID: 29075620 DOI: 10.3389/fcimb.2017.00444] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
21 Sinha T, Vich Vila A, Garmaeva S, Jankipersadsing SA, Imhann F, Collij V, Bonder MJ, Jiang X, Gurry T, Alm EJ, D'Amato M, Weersma RK, Scherjon S, Wijmenga C, Fu J, Kurilshikov A, Zhernakova A. Analysis of 1135 gut metagenomes identifies sex-specific resistome profiles. Gut Microbes 2019;10:358-66. [PMID: 30373468 DOI: 10.1080/19490976.2018.1528822] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
22 Watanabe K, Shimodaira Y, Takahashi S, Fukuda S, Koizumi S, Matsuhashi T, Iijima K. Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection. Am J Gastroenterol 2021;116:1632-7. [PMID: 33989224 DOI: 10.14309/ajg.0000000000001309] [Reference Citation Analysis]
23 Du Y, Gao Y, Zeng B, Fan X, Yang D, Yang M. Effects of anti-aging interventions on intestinal microbiota. Gut Microbes 2021;13:1994835. [PMID: 34743658 DOI: 10.1080/19490976.2021.1994835] [Reference Citation Analysis]
24 Vinke P, Wesselink E, van Orten-Luiten W, van Norren K. The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses. Int J Mol Sci 2020;21:E323. [PMID: 31947724 DOI: 10.3390/ijms21010323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Ilhan ZE, DiBaise JK, Isern NG, Hoyt DW, Marcus AK, Kang DW, Crowell MD, Rittmann BE, Krajmalnik-Brown R. Distinctive microbiomes and metabolites linked with weight loss after gastric bypass, but not gastric banding. ISME J 2017;11:2047-58. [PMID: 28548658 DOI: 10.1038/ismej.2017.71] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 12.6] [Reference Citation Analysis]
26 Wellens J, Sabino J, Vermeire S. PPIs and anti-TNF in patients with IBD: a forbidden combination? Gut 2021:gutjnl-2021-324040. [PMID: 33514599 DOI: 10.1136/gutjnl-2021-324040] [Reference Citation Analysis]
27 Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res 2017;179:204-22. [PMID: 27591027 DOI: 10.1016/j.trsl.2016.08.002] [Cited by in Crossref: 238] [Cited by in F6Publishing: 202] [Article Influence: 39.7] [Reference Citation Analysis]
28 Abe K, Takahashi A, Fujita M, Imaizumi H, Hayashi M, Okai K, Ohira H. Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. PLoS One 2018;13:e0198757. [PMID: 29969462 DOI: 10.1371/journal.pone.0198757] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
29 Park SY, Hwang BO, Lim M, Ok SH, Lee SK, Chun KS, Park KK, Hu Y, Chung WY, Song NY. Oral-Gut Microbiome Axis in Gastrointestinal Disease and Cancer. Cancers (Basel) 2021;13:2124. [PMID: 33924899 DOI: 10.3390/cancers13092124] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Chang TE, Huang YS, Perng CL, Huang YH, Hou MC. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis. J Chin Med Assoc 2019;82:756-61. [PMID: 31335628 DOI: 10.1097/JCMA.0000000000000157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Rounis K, Makrakis D, Papadaki C, Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I, Tsamardinos I, Mavroudis D, Agelaki S. Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study. PLoS One 2021;16:e0252537. [PMID: 34061904 DOI: 10.1371/journal.pone.0252537] [Reference Citation Analysis]
32 Xiong J, Wang Y, Xu W, Liu Z, Wang H, Zhang Z, Han Y, Yin C, Cao S, Yang Z, Su T, Wei J, Chen G, Jin L. Proton pump inhibitors and odds of cholangiocarcinoma: A retrospective case‐control study. Liver Int 2020;40:2848-57. [DOI: 10.1111/liv.14663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Bodai BI, Nakata TE. Breast Cancer: Lifestyle, the Human Gut Microbiota/Microbiome, and Survivorship. Perm J 2020;24. [PMID: 32589577 DOI: 10.7812/TPP/19.129] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Guzman L, Qiu F, Kalil AC, Mercer DF, Langnas A, Florescu DF. Risk factors for Clostridium difficile infection in intestinal transplant recipients during the first year post-transplant. Transpl Infect Dis 2018;20:e12858. [PMID: 29427406 DOI: 10.1111/tid.12858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Yang L, Bajinka O, Jarju PO, Tan Y, Taal AM, Ozdemir G. The varying effects of antibiotics on gut microbiota. AMB Express 2021;11:116. [PMID: 34398323 DOI: 10.1186/s13568-021-01274-w] [Reference Citation Analysis]
36 Moran-Ramos S, López-Contreras BE, Canizales-Quinteros S. Gut Microbiota in Obesity and Metabolic Abnormalities: A Matter of Composition or Functionality? Arch Med Res 2017;48:735-53. [PMID: 29292011 DOI: 10.1016/j.arcmed.2017.11.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
37 Szychowiak P, Villageois-Tran K, Patrier J, Timsit JF, Ruppé É. The role of the microbiota in the management of intensive care patients. Ann Intensive Care 2022;12:3. [PMID: 34985651 DOI: 10.1186/s13613-021-00976-5] [Reference Citation Analysis]
38 Wu Q, Savidge TC. Systems approaches for the clinical diagnosis of Clostridioides difficile infection. Transl Res 2020;220:57-67. [PMID: 32272094 DOI: 10.1016/j.trsl.2020.03.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
40 Wijmenga C, Zhernakova A. The importance of cohort studies in the post-GWAS era. Nat Genet 2018;50:322-8. [PMID: 29511284 DOI: 10.1038/s41588-018-0066-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
41 Choy A, Freedberg DE. Impact of microbiome-based interventions on gastrointestinal pathogen colonization in the intensive care unit. Therap Adv Gastroenterol 2020;13:1756284820939447. [PMID: 32733601 DOI: 10.1177/1756284820939447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Paroni Sterbini F, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, Bugli F, Martini C, Ricciardi W, Gasbarrini A, Sanguinetti M, Cammarota G, Posteraro B. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. Appl Environ Microbiol. 2016;82:6633-6644. [PMID: 27590821 DOI: 10.1128/aem.01437-16] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
43 Chuang S, Lin C, Peng C, Huang W, Su W, Lai S, Lai H. Proton pump inhibitors increase the risk of cholecystitis: a population-based case–control study. Gut 2019;68:1337-9. [DOI: 10.1136/gutjnl-2018-316899] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
44 Zhang Y, Chen J, Fu H, Kuang S, He F, Zhang M, Shen Z, Qin W, Lin Z, Huang S. Exosomes derived from 3D-cultured MSCs improve therapeutic effects in periodontitis and experimental colitis and restore the Th17 cell/Treg balance in inflamed periodontium. Int J Oral Sci 2021;13:43. [PMID: 34907166 DOI: 10.1038/s41368-021-00150-4] [Reference Citation Analysis]
45 Shurney D, Pauly K. The Gut Microbiome and Food as Medicine: Healthy Microbiomes = Healthy Humans. Am J Health Promot 2019;33:821-4. [DOI: 10.1177/0890117119845711b] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
46 Kaesler N, Schreibing F, Speer T, Puente-Secades S, Rapp N, Drechsler C, Kabgani N, Kuppe C, Boor P, Jankowski V, Schurgers L, Kramann R, Floege J. Altered vitamin K biodistribution and metabolism in experimental and human chronic kidney disease. Kidney Int 2021:S0085-2538(21)01056-5. [PMID: 34774554 DOI: 10.1016/j.kint.2021.10.029] [Reference Citation Analysis]
47 Proffitt C, Bidkhori G, Moyes D, Shoaie S. Disease, Drugs and Dysbiosis: Understanding Microbial Signatures in Metabolic Disease and Medical Interventions. Microorganisms 2020;8:E1381. [PMID: 32916966 DOI: 10.3390/microorganisms8091381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
48 Johnson SS, Shurney D, Pauly K, Mauriello LM, Artz K, Hess A, Passaretti M, Coolbaugh S, Martin P, Classens K, Fox J, Kass A. Editor's Desk: Masterful Microbes: The Gut Microbiome and Food as Medicine. Am J Health Promot 2019;33:820-34. [PMID: 31079468 DOI: 10.1177/0890117119845711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
50 Caesar R. Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes. Can J Diabetes 2019;43:224-31. [PMID: 30929665 DOI: 10.1016/j.jcjd.2019.01.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
51 Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep. 2017;19:42. [PMID: 28733944 DOI: 10.1007/s11894-017-0577-6] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
52 Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:1453-68. [PMID: 32969507 DOI: 10.1111/apt.16096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
53 Maharshak N, Barzilay I, Zinger H, Hod K, Dotan I. Clostridium difficile infection in hospitalized patients with inflammatory bowel disease: Prevalence, risk factors, and prognosis. Medicine (Baltimore) 2018;97:e9772. [PMID: 29384868 DOI: 10.1097/MD.0000000000009772] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
54 Imhann F, Vich Vila A, Bonder MJ, Fu J, Gevers D, Visschedijk MC, Spekhorst LM, Alberts R, Franke L, van Dullemen HM, Ter Steege RWF, Huttenhower C, Dijkstra G, Xavier RJ, Festen EAM, Wijmenga C, Zhernakova A, Weersma RK. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Gut 2018;67:108-19. [PMID: 27802154 DOI: 10.1136/gutjnl-2016-312135] [Cited by in Crossref: 289] [Cited by in F6Publishing: 282] [Article Influence: 48.2] [Reference Citation Analysis]
55 Verhoeckx K, Bøgh KL, Dupont D, Egger L, Gadermaier G, Larré C, Mackie A, Menard O, Adel-Patient K, Picariello G, Portmann R, Smit J, Turner P, Untersmayr E, Epstein MM. The relevance of a digestibility evaluation in the allergenicity risk assessment of novel proteins. Opinion of a joint initiative of COST action ImpARAS and COST action INFOGEST. Food Chem Toxicol 2019;129:405-23. [PMID: 31063834 DOI: 10.1016/j.fct.2019.04.052] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
56 Liebert A, Bicknell B, Johnstone DM, Gordon LC, Kiat H, Hamblin MR. "Photobiomics": Can Light, Including Photobiomodulation, Alter the Microbiome? Photobiomodul Photomed Laser Surg 2019;37:681-93. [PMID: 31596658 DOI: 10.1089/photob.2019.4628] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
57 Avelar Rodriguez D, Peña Vélez R, Toro Monjaraz EM, Ramirez Mayans J, Ryan PM. The Gut Microbiota: A Clinically Impactful Factor in Patient Health and Disease. SN Compr Clin Med 2019;1:188-99. [DOI: 10.1007/s42399-018-0036-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
58 Jordakieva G, Kundi M, Untersmayr E, Pali-Schöll I, Reichardt B, Jensen-Jarolim E. Country-wide medical records infer increased allergy risk of gastric acid inhibition. Nat Commun 2019;10:3298. [PMID: 31363098 DOI: 10.1038/s41467-019-10914-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
59 Latour K, Huang TD, Jans B, Berhin C, Bogaerts P, Noel A, Nonhoff C, Dodémont M, Denis O, Ieven M, Loens K, Schoevaerdts D, Catry B, Glupczynski Y. Prevalence of multidrug-resistant organisms in nursing homes in Belgium in 2015. PLoS One 2019;14:e0214327. [PMID: 30921364 DOI: 10.1371/journal.pone.0214327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
60 Roberts AB, Gu X, Buffa JA, Hurd AG, Wang Z, Zhu W, Gupta N, Skye SM, Cody DB, Levison BS, Barrington WT, Russell MW, Reed JM, Duzan A, Lang JM, Fu X, Li L, Myers AJ, Rachakonda S, DiDonato JA, Brown JM, Gogonea V, Lusis AJ, Garcia-Garcia JC, Hazen SL. Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med. 2018;24:1407-1417. [PMID: 30082863 DOI: 10.1038/s41591-018-0128-1] [Cited by in Crossref: 182] [Cited by in F6Publishing: 168] [Article Influence: 45.5] [Reference Citation Analysis]
61 Hayes KN, Nakhla NR, Tadrous M. Further Evidence to Monitor Long-term Proton Pump Inhibitor Use. JAMA Netw Open 2019;2:e1916184. [DOI: 10.1001/jamanetworkopen.2019.16184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Hopkins AM, Kichenadasse G, McKinnon RA, Abuhelwa AY, Logan JM, Badaoui S, Karapetis CS, Rowland A, Sorich MJ. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer 2021. [PMID: 34711947 DOI: 10.1038/s41416-021-01606-4] [Reference Citation Analysis]
63 Samadi N, Klems M, Untersmayr E. The role of gastrointestinal permeability in food allergy. Ann Allergy Asthma Immunol 2018;121:168-73. [PMID: 29803708 DOI: 10.1016/j.anai.2018.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
64 Horvath A, Stadlbauer V. [Proton Pump Inhibitors and their Microbiome-Mediated Side Effects]. Zentralbl Chir 2021;146:165-9. [PMID: 33327006 DOI: 10.1055/a-1312-7587] [Reference Citation Analysis]
65 D'Souza SM, Houston K, Keenan L, Yoo BS, Parekh PJ, Johnson DA. Role of microbial dysbiosis in the pathogenesis of esophageal mucosal disease: A paradigm shift from acid to bacteria? World J Gastroenterol 2021; 27(18): 2054-2072 [PMID: 34025064 DOI: 10.3748/wjg.v27.i18.2054] [Reference Citation Analysis]
66 Rosener B, Sayin S, Oluoch PO, García González AP, Mori H, Walhout AJ, Mitchell A. Evolved bacterial resistance against fluoropyrimidines can lower chemotherapy impact in the Caenorhabditis elegans host. Elife 2020;9:e59831. [PMID: 33252330 DOI: 10.7554/eLife.59831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Durack J, Lynch SV. The gut microbiome: Relationships with disease and opportunities for therapy. J Exp Med. 2019;216:20-40. [PMID: 30322864 DOI: 10.1084/jem.20180448] [Cited by in Crossref: 182] [Cited by in F6Publishing: 147] [Article Influence: 45.5] [Reference Citation Analysis]
68 Wauters L, Talley NJ, Walker MM, Tack J, Vanuytsel T. Novel concepts in the pathophysiology and treatment of functional dyspepsia. Gut 2020;69:591-600. [DOI: 10.1136/gutjnl-2019-318536] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 12.3] [Reference Citation Analysis]
69 Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD, Ang TL. Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore. Singapore Med J 2019;60:512-21. [PMID: 30488079 DOI: 10.11622/smedj.2018152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
70 Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, Zhong H, Liu Z, Gao Y, Zhao H, Zhang D, Su Z, Fang Z, Lan Z, Li J, Xiao L, Li J, Li R, Li X, Li F, Ren H, Huang Y, Peng Y, Li G, Wen B, Dong B, Chen JY, Geng QS, Zhang ZW, Yang H, Wang J, Wang J, Zhang X, Madsen L, Brix S, Ning G, Xu X, Liu X, Hou Y, Jia H, He K, Kristiansen K. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. [PMID: 29018189 DOI: 10.1038/s41467-017-00900-1] [Cited by in Crossref: 424] [Cited by in F6Publishing: 400] [Article Influence: 84.8] [Reference Citation Analysis]
71 Haran JP, Ward DV, Bhattarai SK, Loew E, Dutta P, Higgins A, McCormick BA, Bucci V. The high prevalence of Clostridioides difficile among nursing home elders associates with a dysbiotic microbiome. Gut Microbes 2021;13:1-15. [PMID: 33764826 DOI: 10.1080/19490976.2021.1897209] [Reference Citation Analysis]
72 Yap TW, Leow AH, Azmi AN, Callahan DL, Perez-Perez GI, Loke MF, Goh KL, Vadivelu J. Global Fecal and Plasma Metabolic Dynamics Related to Helicobacter pylori Eradication. Front Microbiol 2017;8:536. [PMID: 28424674 DOI: 10.3389/fmicb.2017.00536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
73 Shah A, Talley NJ, Koloski N, Macdonald GA, Kendall BJ, Shanahan ER, Walker MM, Keely S, Jones MP, Morrison M, Holtmann GJ. Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:155-67. [PMID: 32412673 DOI: 10.1111/apt.15786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
74 Puga AM, Lopez-Oliva S, Trives C, Partearroyo T, Varela-Moreiras G. Effects of Drugs and Excipients on Hydration Status. Nutrients 2019;11:E669. [PMID: 30897748 DOI: 10.3390/nu11030669] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
75 Parsons E, Claud K, Petrof EO. The infant microbiome and implications for central nervous system development. Prog Mol Biol Transl Sci 2020;171:1-13. [PMID: 32475519 DOI: 10.1016/bs.pmbts.2020.04.007] [Reference Citation Analysis]
76 Babic A, Zhang X, Morales-Oyarvide V, Yuan C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, Wu K, Fuchs CS, Giovannucci EL, Stampfer MJ, Ng K. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer 2020;123:844-51. [PMID: 32541871 DOI: 10.1038/s41416-020-0939-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
77 Dai Y, Tai Y, Chen C, Chang Y, Chen T, Chen M. Use of proton pump inhibitors and risk of rosacea: A nationwide population‐based study. J Dermatol 2020;47:1126-30. [DOI: 10.1111/1346-8138.15478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V. A safety review of proton pump inhibitors to treat acid-related digestive diseases. Expert Opinion on Drug Safety 2018;17:785-94. [DOI: 10.1080/14740338.2018.1497155] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
79 Yamamoto K, Ishigami M, Honda T, Takeyama T, Ito T, Ishizu Y, Kuzuya T, Hayashi K, Goto H, Hirooka Y. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatol Int 2019;13:234-44. [DOI: 10.1007/s12072-019-09932-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
80 Iwaki M, Kessoku T, Ozaki A, Kasai Y, Kobayashi T, Nogami A, Honda Y, Ogawa Y, Imajo K, Yoneda M, Maeda A, Tanaka Y, Nakajima S, Ohno H, Usuda H, Kawanaka M, Kawaguchi T, Torimura T, Kage M, Hyogo H, Takahashi H, Eguchi Y, Aishima S, Wada K, Kobayashi N, Sumida Y, Saito S, Nakajima A. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:2275-84. [PMID: 33709477 DOI: 10.1111/jgh.15487] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
81 Ducarmon QR, Zwittink RD, Hornung BVH, van Schaik W, Young VB, Kuijper EJ. Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection. Microbiol Mol Biol Rev 2019;83:e00007-19. [PMID: 31167904 DOI: 10.1128/MMBR.00007-19] [Cited by in Crossref: 78] [Cited by in F6Publishing: 48] [Article Influence: 26.0] [Reference Citation Analysis]
82 Vilcu AM, Sabatte L, Blanchon T, Souty C, Maravic M, Lemaitre M, Steichen O, Hanslik T. Association Between Acute Gastroenteritis and Continuous Use of Proton Pump Inhibitors During Winter Periods of Highest Circulation of Enteric Viruses. JAMA Netw Open 2019;2:e1916205. [PMID: 31774521 DOI: 10.1001/jamanetworkopen.2019.16205] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
83 Schmidt TS, Hayward MR, Coelho LP, Li SS, Costea PI, Voigt AY, Wirbel J, Maistrenko OM, Alves RJ, Bergsten E, de Beaufort C, Sobhani I, Heintz-Buschart A, Sunagawa S, Zeller G, Wilmes P, Bork P. Extensive transmission of microbes along the gastrointestinal tract. Elife. 2019;8. [PMID: 30747106 DOI: 10.7554/elife.42693] [Cited by in Crossref: 87] [Cited by in F6Publishing: 64] [Article Influence: 29.0] [Reference Citation Analysis]
84 Kim JW, Jeong Y, Park SJ, Jin H, Lee J, Ju JH, Ji GE, Park SH. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology (Oxford) 2021;60:708-16. [PMID: 32789440 DOI: 10.1093/rheumatology/keaa316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Reese AT, Dunn RR. Drivers of Microbiome Biodiversity: A Review of General Rules, Feces, and Ignorance. mBio 2018;9:e01294-18. [PMID: 30065092 DOI: 10.1128/mBio.01294-18] [Cited by in Crossref: 99] [Cited by in F6Publishing: 59] [Article Influence: 24.8] [Reference Citation Analysis]
86 Naghipour S, Cox AJ, Peart JN, Du Toit EF, Headrick JP. Trimethylamine N-oxide: heart of the microbiota-CVD nexus? Nutr Res Rev 2021;34:125-46. [PMID: 32718365 DOI: 10.1017/S0954422420000177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Sturm L, Bettinger D, Giesler M, Boettler T, Schmidt A, Buettner N, Thimme R, Schultheiss M. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS). United European Gastroenterol J 2018;6:1380-90. [PMID: 30386611 DOI: 10.1177/2050640618795928] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
88 Rohana H, Azrad M, Nitzan O, Adler A, Binyamin D, Koren O, Peretz A. Characterization of Clostridioides difficile Strains, the Disease Severity, and the Microbial Changes They Induce. J Clin Med 2020;9:E4099. [PMID: 33353133 DOI: 10.3390/jcm9124099] [Reference Citation Analysis]
89 Boer CG, Radjabzadeh D, Medina-Gomez C, Garmaeva S, Schiphof D, Arp P, Koet T, Kurilshikov A, Fu J, Ikram MA, Bierma-Zeinstra S, Uitterlinden AG, Kraaij R, Zhernakova A, van Meurs JBJ. Intestinal microbiome composition and its relation to joint pain and inflammation. Nat Commun 2019;10:4881. [PMID: 31653850 DOI: 10.1038/s41467-019-12873-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
90 Janabi A, Biddle A, Klein D, Mckeever K. Exercise training-induced changes in the gut microbiota of Standardbred racehorses. Comparative Exercise Physiology 2016;12:119-30. [DOI: 10.3920/cep160015] [Cited by in Crossref: 10] [Article Influence: 1.7] [Reference Citation Analysis]
91 Bharwani A, Bala A, Surette M, Bienenstock J, Vigod SN, Taylor VH. Gut Microbiome Patterns Associated With Treatment Response in Patients With Major Depressive Disorder. Can J Psychiatry 2020;65:278-80. [PMID: 31958990 DOI: 10.1177/0706743719900464] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
92 Macke L, Schulz C, Koletzko L, Malfertheiner P. Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies. Aliment Pharmacol Ther. 2020;51:505-526. [PMID: 31990420 DOI: 10.1111/apt.15604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
93 Cheung KS, Lam LK, Seto WK, Leung WK. Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma. Liver Cancer 2021;10:606-14. [PMID: 34950183 DOI: 10.1159/000518090] [Reference Citation Analysis]
94 Samarkos M, Mastrogianni E, Kampouropoulou O. The role of gut microbiota in Clostridium difficile infection. Eur J Intern Med 2018;50:28-32. [PMID: 29428498 DOI: 10.1016/j.ejim.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
95 Espinoza JL, Matsumoto A, Tanaka H, Matsumura I. Gastric microbiota: An emerging player in Helicobacter pylori-induced gastric malignancies. Cancer Lett. 2018;414:147-152. [PMID: 29138097 DOI: 10.1016/j.canlet.2017.11.009] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
96 Wang J, Du W, Xu Y, Cheng S, Liu Z. Gut microbiome-based medical methodologies for early-stage disease prevention. Microbial Pathogenesis 2017;105:122-30. [DOI: 10.1016/j.micpath.2017.02.024] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
97 Fukuokaya W, Egawa S. Re: Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2021;79:553-4. [PMID: 33277082 DOI: 10.1016/j.eururo.2020.11.033] [Reference Citation Analysis]
98 Seo SI, Park CH, You SC, Kim JY, Lee KJ, Kim J, Kim Y, Yoo JJ, Seo WW, Lee HS, Shin WG. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut 2021:gutjnl-2020-323845. [PMID: 33975868 DOI: 10.1136/gutjnl-2020-323845] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
99 Ross CL, Spinler JK, Savidge TC. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Anaerobe 2016;41:37-43. [PMID: 27180006 DOI: 10.1016/j.anaerobe.2016.05.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
100 Haran JP, McCormick BA. Aging, Frailty, and the Microbiome-How Dysbiosis Influences Human Aging and Disease. Gastroenterology 2021;160:507-23. [PMID: 33307030 DOI: 10.1053/j.gastro.2020.09.060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
101 Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker MG, Nigro O, Tanda E, Russo A. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Crit Rev Oncol Hematol 2019;142:26-34. [PMID: 31352168 DOI: 10.1016/j.critrevonc.2019.07.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
102 Jeffery IB, Das A, O'Herlihy E, Coughlan S, Cisek K, Moore M, Bradley F, Carty T, Pradhan M, Dwibedi C, Shanahan F, O'Toole PW. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. Gastroenterology 2020;158:1016-1028.e8. [PMID: 31843589 DOI: 10.1053/j.gastro.2019.11.301] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 12.7] [Reference Citation Analysis]
103 Zubeidat K, Hovav AH. Shaped by the epithelium - postnatal immune mechanisms of oral homeostasis. Trends Immunol 2021;42:622-34. [PMID: 34083119 DOI: 10.1016/j.it.2021.05.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Mulder M, Arp PP, Kiefte-de Jong JC, Uitterlinden AG, Klaassen CHW, Kraaij R, Goessens WHF, Verbon A, Stricker BH. Prevalence of and risk factors for extended-spectrum beta-lactamase genes carriership in a population-based cohort of middle-aged and elderly. Int J Antimicrob Agents 2021;58:106388. [PMID: 34161788 DOI: 10.1016/j.ijantimicag.2021.106388] [Reference Citation Analysis]
105 Bloomfield LE, Riley TV. Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review. Infect Dis Ther 2016;5:231-51. [PMID: 27370914 DOI: 10.1007/s40121-016-0117-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
106 Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors. Front Immunol 2021;12:716317. [PMID: 34777340 DOI: 10.3389/fimmu.2021.716317] [Reference Citation Analysis]
107 Dong T, Pisegna J. Passing the "Acid Test": Do Proton Pump Inhibitors Affect the Composition of the Microbiome? Dig Dis Sci 2018;63:2817-9. [PMID: 30218426 DOI: 10.1007/s10620-018-5273-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
108 Hong AS, Yu WY, Hong JM, Cross CL, Azab M, Ohning G, Jayaraj M. Proton pump inhibitor in upper gastrointestinal fecal microbiota transplant: A systematic review and analysis. J Gastroenterol Hepatol 2020;35:932-40. [PMID: 31830335 DOI: 10.1111/jgh.14958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
109 Ishioka M, Watanabe N, Sawaguchi M, Fukuda S, Shiga H, Matsuhashi T, Jin M, Iijima K. Phlegmonous Gastritis: A Report of Three Cases with Clinical and Imaging Features. Intern Med 2018;57:2185-8. [PMID: 29607969 DOI: 10.2169/internalmedicine.0707-17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
110 Stacchiotti V, Rezzi S, Eggersdorfer M, Galli F. Metabolic and functional interplay between gut microbiota and fat-soluble vitamins. Crit Rev Food Sci Nutr 2020;:1-22. [PMID: 32715724 DOI: 10.1080/10408398.2020.1793728] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
111 Haran JP, Zeamer A, Ward DV, Dutta P, Bucci V, McCormick BA. The Nursing Home Older Adult Gut Microbiome Composition Shows Time-dependent Dysbiosis and is Influenced by Medication Exposures, Age, Environment, and Frailty. J Gerontol A Biol Sci Med Sci 2021:glab167. [PMID: 34125200 DOI: 10.1093/gerona/glab167] [Reference Citation Analysis]
112 Wei J, Chan AT, Zeng C, Bai X, Lu N, Lei G, Zhang Y. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study. Bone 2020;139:115502. [PMID: 32593677 DOI: 10.1016/j.bone.2020.115502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
113 Wang Y, Liu F, Zhang G, Su Y, Sun X, Chen Q, Wang C, Fu H, He Y, Zhu X, Liu X, Lv M, Zhao X, Zhao X, Li Y, Wang Q, Huang X, Zhang X. Gut microbiome alterations and its link to corticosteroid resistance in immune thrombocytopenia. Sci China Life Sci 2021;64:766-83. [PMID: 32857289 DOI: 10.1007/s11427-020-1788-2] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
114 Silva M, Brunner V, Tschurtschenthaler M. Microbiota and Colorectal Cancer: From Gut to Bedside. Front Pharmacol 2021;12:760280. [PMID: 34658896 DOI: 10.3389/fphar.2021.760280] [Reference Citation Analysis]
115 Horvath A, Bausys A, Sabaliauskaite R, Stratilatovas E, Jarmalaite S, Schuetz B, Stiegler P, Bausys R, Stadlbauer V, Strupas K. Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study. Ann Surg Oncol. 2021;28:1198-1208. [PMID: 32504369 DOI: 10.1245/s10434-020-08678-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
116 Javaudin F, Bémer P, Batard E, Montassier E. Impact of Phage Therapy on Multidrug-Resistant Escherichia coli Intestinal Carriage in a Murine Model. Microorganisms 2021;9:2580. [PMID: 34946183 DOI: 10.3390/microorganisms9122580] [Reference Citation Analysis]
117 Singh A, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. Nutr Clin Pract. 2018;33:614-624. [PMID: 30071147 DOI: 10.1002/ncp.10181] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
118 Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications. BMC Cancer 2020;20:383. [PMID: 32375706 DOI: 10.1186/s12885-020-06882-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
119 Zhong H, Lin D, Lu Z, Yang W, Chen Y. Use of gastric-acid suppressants may be a risk factor for enteric peritonitis in patients undergoing peritoneal dialysis: A meta-analysis. J Clin Pharm Ther 2019;44:209-15. [DOI: 10.1111/jcpt.12769] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
120 Chris-Olaiya A, Palmer W, Stancampiano F, Lacy B, Heckman M, Chirila R, Nikpour N, Mcleod E, Ryan T, Maillis A, Vargas E, Bouras E. Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice. Rom J Intern Med 2020;58:228-32. [PMID: 32543459 DOI: 10.2478/rjim-2020-0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
121 Tilg H, Adolph TE. Beyond Digestion: The Pancreas Shapes Intestinal Microbiota and Immunity. Cell Metab. 2017;25:495-496. [PMID: 28273472 DOI: 10.1016/j.cmet.2017.02.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
122 Lee C, Hong SN. Does Long-Term Proton Pump Inhibitor Therapy Affect the Health of Gut Microbiota? Gut Liver 2016;10:865-6. [PMID: 27784840 DOI: 10.5009/gnl16438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
123 Almeida-Santos A, Martins-Mendes D, Gayà-Vidal M, Pérez-Pardal L, Beja-Pereira A. Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients. Front Microbiol 2021;12:610370. [PMID: 33613481 DOI: 10.3389/fmicb.2021.610370] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Ma X, Huang L, Huang Z, Jiang J, Zhao C, Tong H, Feng Z, Gao J, Liu R, Zhang M, Zhou M, Tan Q, Liu L, Tang C. The impacts of acid suppression on duodenal microbiota during the early phase of severe acute pancreatitis. Sci Rep 2020;10:20063. [PMID: 33208878 DOI: 10.1038/s41598-020-77245-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 2017; Epub ahead of print. [PMID: 29273641 DOI: 10.1136/gutjnl-2017-315710] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
126 Quigley EMM, Gajula P. Recent advances in modulating the microbiome. F1000Res 2020;9:F1000 Faculty Rev-46. [PMID: 32047611 DOI: 10.12688/f1000research.20204.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
127 Maseda D, Ricciotti E. NSAID-Gut Microbiota Interactions. Front Pharmacol. 2020;11:1153. [PMID: 32848762 DOI: 10.3389/fphar.2020.01153] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
128 Chisari E, Wouthuyzen-Bakker M, Friedrich AW, Parvizi J. The relation between the gut microbiome and osteoarthritis: A systematic review of literature. PLoS One 2021;16:e0261353. [PMID: 34914764 DOI: 10.1371/journal.pone.0261353] [Reference Citation Analysis]
129 Maksimaityte V, Bausys A, Kryzauskas M, Luksta M, Stundiene I, Bickaite K, Bausys B, Poskus T, Bausys R, Strupas K. Gastrectomy impact on the gut microbiome in patients with gastric cancer: A comprehensive review. World J Gastrointest Surg 2021; 13(7): 678-688 [PMID: 34354801 DOI: 10.4240/wjgs.v13.i7.678] [Reference Citation Analysis]
130 Hudson LE, Anderson SE, Corbett AH, Lamb TJ. Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. Clin Microbiol Rev. 2017;30:191-231. [PMID: 27856521 DOI: 10.1128/cmr.00049-16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
131 Wongtrakul W, Charoenngnam N, Ungprasert P. Use of proton pump inhibitors is associated with a higher risk of pneumonia in cirrhotic patients: a systematic review and meta-analysis. Ann Gastroenterol 2020;33:277-84. [PMID: 32382231 DOI: 10.20524/aog.2020.0483] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Drall KM, Tun HM, Kozyrskyj AL. Commentary: The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A Prospective Longitudinal Interventional Study. Front Cell Infect Microbiol 2018;8:430. [PMID: 30619776 DOI: 10.3389/fcimb.2018.00430] [Reference Citation Analysis]
133 Sun S, Ye W, Zhao R, Hu J, Zhang X, Yang M, Zhao H, Sheng J. Proton Pump Inhibitor Therapy Does Not Affect Prognosis of Cirrhosis Patients With Acute Decompensation and Acute-on-Chronic Liver Failure: A Single-Center Prospective Study. Front Med (Lausanne) 2021;8:763370. [PMID: 34859015 DOI: 10.3389/fmed.2021.763370] [Reference Citation Analysis]
134 Mcgovern AS, Hamlin AS, Winter G. A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. Aust N Z J Psychiatry 2019;53:1151-66. [DOI: 10.1177/0004867419877954] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
135 Chen L, Garmaeva S, Zhernakova A, Fu J, Wijmenga C. A system biology perspective on environment–host–microbe interactions. Human Molecular Genetics 2018;27:R187-94. [DOI: 10.1093/hmg/ddy137] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
136 Novotny M, Klimova B, Valis M. PPI Long Term Use: Risk of Neurological Adverse Events? Front Neurol 2018;9:1142. [PMID: 30671013 DOI: 10.3389/fneur.2018.01142] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
137 Yang YSH, Chang HW, Lin IH, Chien LN, Wu MJ, Liu YR, Chu PG, Xie G, Dong F, Jia W, Chang VHS, Yen Y. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Sci Rep 2020;10:866. [PMID: 31964941 DOI: 10.1038/s41598-020-57612-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
138 Villafuerte-gálvez JA, Kelly CP. Proton pump inhibitors and risk of Clostridium difficile infection: association or causation? Current Opinion in Gastroenterology 2018;34:11-8. [DOI: 10.1097/mog.0000000000000414] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
139 Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, Mujagic Z, Jonkers DMAE, Masclee AAM, Fu J, Kurilshikov A, Wijmenga C, Zhernakova A, Weersma RK. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362. [PMID: 31953381 DOI: 10.1038/s41467-019-14177-z] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 51.5] [Reference Citation Analysis]
140 Willems RPJ, van Dijk K, Ket JCF, Vandenbroucke-Grauls CMJE. Evaluation of the Association Between Gastric Acid Suppression and Risk of Intestinal Colonization With Multidrug-Resistant Microorganisms: A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:561-71. [PMID: 32091544 DOI: 10.1001/jamainternmed.2020.0009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
141 Otremba I, Wilczyński K, Szewieczek J. Delirium in the geriatric unit: proton-pump inhibitors and other risk factors. Clin Interv Aging 2016;11:397-405. [PMID: 27103793 DOI: 10.2147/CIA.S103349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
142 Lin YT, Lin TY, Hung SC, Liu PY, Hung WC, Tsai WC, Tsai YC, Delicano RA, Chuang YS, Kuo MC, Chiu YW, Wu PH. Differences in the Microbial Composition of Hemodialysis Patients Treated with and without β-Blockers. J Pers Med 2021;11:198. [PMID: 33809103 DOI: 10.3390/jpm11030198] [Reference Citation Analysis]
143 Bajaj JS, Liu EJ, Kheradman R, Fagan A, Heuman DM, White M, Gavis EA, Hylemon P, Sikaroodi M, Gillevet PM. Fungal dysbiosis in cirrhosis. Gut 2018;67:1146-54. [DOI: 10.1136/gutjnl-2016-313170] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 10.4] [Reference Citation Analysis]
144 Haran JP, Bradley E, Howe E, Wu X, Tjia J. Medication Exposure and Risk of Recurrent Clostridium difficile Infection in Community-Dwelling Older People and Nursing Home Residents. J Am Geriatr Soc 2018;66:333-8. [DOI: 10.1111/jgs.15176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
145 Bosch S, Lemmen JP, Menezes R, van der Hulst R, Kuijvenhoven J, Stokkers PC, de Meij TG, de Boer NK. The influence of lifestyle factors on fecal volatile organic compound composition as measured by an electronic nose. J Breath Res 2019;13:046001. [PMID: 31170704 DOI: 10.1088/1752-7163/ab2775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
146 Tao ZH, Han JX, Fang JY. Helicobacter pylori infection and eradication: Exploring their impacts on the gastrointestinal microbiota. Helicobacter 2020;25:e12754. [PMID: 32876377 DOI: 10.1111/hel.12754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
147 Shiels PG, Painer J, Natterson-Horowitz B, Johnson RJ, Miranda JJ, Stenvinkel P. Manipulating the exposome to enable better ageing. Biochem J 2021;478:2889-98. [PMID: 34319404 DOI: 10.1042/BCJ20200958] [Reference Citation Analysis]
148 Liu F, Ren T, Li X, Zhai Q, Xu X, Zhang N, Jiang P, Niu Y, Lv L, Shi G, Feng N. Distinct Microbiomes of Gut and Saliva in Patients With Systemic Lupus Erythematous and Clinical Associations. Front Immunol 2021;12:626217. [PMID: 34276643 DOI: 10.3389/fimmu.2021.626217] [Reference Citation Analysis]
149 Sun S, Lulla A, Sioda M, Winglee K, Wu MC, Jacobs DR Jr, Shikany JM, Lloyd-Jones DM, Launer LJ, Fodor AA, Meyer KA. Gut Microbiota Composition and Blood Pressure. Hypertension 2019;73:998-1006. [PMID: 30905192 DOI: 10.1161/HYPERTENSIONAHA.118.12109] [Cited by in Crossref: 78] [Cited by in F6Publishing: 45] [Article Influence: 26.0] [Reference Citation Analysis]
150 Schneider KM, Elfers C, Ghallab A, Schneider CV, Galvez EJC, Mohs A, Gui W, Candels LS, Wirtz TH, Zuehlke S, Spiteller M, Myllys M, Roulet A, Ouzerdine A, Lelouvier B, Kilic K, Liao L, Nier A, Latz E, Bergheim I, Thaiss CA, Hengstler JG, Strowig T, Trautwein C. Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury. Cell Mol Gastroenterol Hepatol 2021;11:909-33. [PMID: 33189892 DOI: 10.1016/j.jcmgh.2020.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
151 Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol 2019;17:756-765.e3. [PMID: 30036646 DOI: 10.1016/j.cgh.2018.07.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
152 Furune S, Yamamoto K, Honda T, Fujiyoshi T, Kakushima N, Furukawa K, Ohno E, Nakamura M, Miyahara R, Kawashima H, Ishigami M, Hirooka Y, Fujishiro M. Changes in the gut microbiome in relation to the degree of gastric mucosal atrophy before and after Helicobacter pylori eradication. Scand J Gastroenterol 2021;:1-8. [PMID: 34818132 DOI: 10.1080/00365521.2021.2005135] [Reference Citation Analysis]
153 Cianci R, Franza L, Massaro MG, Borriello R, De Vito F, Gambassi G. The Interplay between Immunosenescence and Microbiota in the Efficacy of Vaccines. Vaccines (Basel) 2020;8:E636. [PMID: 33147686 DOI: 10.3390/vaccines8040636] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
154 Willmann M, Vehreschild MJGT, Biehl LM, Vogel W, Dörfel D, Hamprecht A, Seifert H, Autenrieth IB, Peter S. Distinct impact of antibiotics on the gut microbiome and resistome: a longitudinal multicenter cohort study. BMC Biol 2019;17:76. [PMID: 31533707 DOI: 10.1186/s12915-019-0692-y] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
155 Duncanson K, Burns G, Pryor J, Keely S, Talley NJ. Mechanisms of Food-Induced Symptom Induction and Dietary Management in Functional Dyspepsia. Nutrients 2021;13:1109. [PMID: 33800668 DOI: 10.3390/nu13041109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
157 Jang S, Lebwohl B, Abrams JA, Green PHR, Freedberg DE, Alaedini A. Celiac disease serology and gut microbiome following proton pump inhibitor treatment. Medicine (Baltimore) 2020;99:e21488. [PMID: 32871870 DOI: 10.1097/MD.0000000000021488] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
158 Lewis DS, Lee T, Konanur M, Ziegler C, Hall MD, Pabon-ramos WM, Suhocki PV, Smith TP, Kim CY, Choi SS, Ronald J. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation. Journal of Vascular and Interventional Radiology 2019;30:163-9. [DOI: 10.1016/j.jvir.2018.10.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
159 Koulouridi A, Messaritakis I, Gouvas N, Tsiaoussis J, Souglakos J. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer. Cancers (Basel) 2020;13:E43. [PMID: 33375686 DOI: 10.3390/cancers13010043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
160 Macpherson AJ. Do the Microbiota Influence Vaccines and Protective Immunity to Pathogens? Issues of Sovereignty, Federalism, and Points-Testing in the Prokaryotic and Eukaryotic Spaces of the Host-Microbial Superorganism. Cold Spring Harb Perspect Biol 2018;10:a029363. [PMID: 28432128 DOI: 10.1101/cshperspect.a029363] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
161 Rashidi A, Weisdorf DJ. Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. Transl Res 2020;220:167-81. [PMID: 32275896 DOI: 10.1016/j.trsl.2020.03.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
162 Ortiz AM, Flynn JK, DiNapoli SR, Sortino O, Vujkovic-Cvijin I, Belkaid Y, Sereti I, Brenchley JM. Antiretroviral Therapy Administration in Healthy Rhesus Macaques Is Associated with Transient Shifts in Intestinal Bacterial Diversity and Modest Immunological Perturbations. J Virol 2019;93:e00472-19. [PMID: 31270225 DOI: 10.1128/JVI.00472-19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
163 Helin N, Kolho KL, Merras-Salmio L. Parentally reported early childhood upper gastrointestinal symptoms alleviate at school age. Acta Paediatr 2021. [PMID: 34516678 DOI: 10.1111/apa.16106] [Reference Citation Analysis]
164 Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018;555:623-628. [PMID: 29555994 DOI: 10.1038/nature25979] [Cited by in Crossref: 709] [Cited by in F6Publishing: 602] [Article Influence: 177.3] [Reference Citation Analysis]
165 Kuo SM. Does Modification of the Large Intestinal Microbiome Contribute to the Anti-Inflammatory Activity of Fermentable Fiber? Curr Dev Nutr 2018;2:nzx004. [PMID: 30377676 DOI: 10.3945/cdn.117.001180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
166 Yoshihara T, Oikawa Y, Kato T, Kessoku T, Kobayashi T, Kato S, Misawa N, Ashikari K, Fuyuki A, Ohkubo H, Higurashi T, Tateishi Y, Tanaka Y, Nakajima S, Ohno H, Wada K, Nakajima A. The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin. Gut Microbes 2020;11:1385-404. [PMID: 32515658 DOI: 10.1080/19490976.2020.1758290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
167 von Martels JZH, Sadaghian Sadabad M, Bourgonje AR, Blokzijl T, Dijkstra G, Faber KN, Harmsen HJM. The role of gut microbiota in health and disease: In vitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. Anaerobe. 2017;44:3-12. [PMID: 28062270 DOI: 10.1016/j.anaerobe.2017.01.001] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 13.4] [Reference Citation Analysis]
168 Li M, Zeng C, Yao J, Ge Y, An G. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy. Int Immunopharmacol 2020;88:106972. [PMID: 33182025 DOI: 10.1016/j.intimp.2020.106972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
169 Lucendo AJ. Drug Exposure and the Risk of Microscopic Colitis: A Critical Update. Drugs R D 2017;17:79-89. [PMID: 28101837 DOI: 10.1007/s40268-016-0171-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
170 Kurilshikov A, Wijmenga C, Fu J, Zhernakova A. Host Genetics and Gut Microbiome: Challenges and Perspectives. Trends Immunol 2017;38:633-47. [PMID: 28669638 DOI: 10.1016/j.it.2017.06.003] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 26.4] [Reference Citation Analysis]
171 Tasnim S, Miller AL, Jupiter DC, Hamilton CF, Reep GL, Krill TS, Pyles RB, Okereke IC. Effects of proton pump inhibitor use on the esophageal microbial community. BMC Gastroenterol 2020;20:312. [PMID: 32967615 DOI: 10.1186/s12876-020-01460-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
172 Chen HY, Lin JJ, Yang B, Lin MC. Risk of systemic autoimmune diseases in gastric disease patients with proton pump inhibitor use: a nationwide cohort study in Taiwan. Clin Rheumatol 2020;39:2773-80. [PMID: 32152918 DOI: 10.1007/s10067-020-05012-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Streit F, Prandovszky E, Send T, Zillich L, Frank J, Sabunciyan S, Foo J, Sirignano L, Lange B, Bardtke S, Hatfield G, Witt SH, Gilles M, Rietschel M, Deuschle M, Yolken R. Microbiome profiles are associated with cognitive functioning in 45-month-old children. Brain Behav Immun 2021;98:151-60. [PMID: 34371134 DOI: 10.1016/j.bbi.2021.08.001] [Reference Citation Analysis]
174 Olekhnovich EI, Manolov AI, Samoilov AE, Prianichnikov NA, Malakhova MV, Tyakht AV, Pavlenko AV, Babenko VV, Larin AK, Kovarsky BA, Starikova EV, Glushchenko OE, Safina DD, Markelova MI, Boulygina EA, Khusnutdinova DR, Malanin SY, Abdulkhakov SR, Abdulkhakov RA, Grigoryeva TV, Kostryukova ES, Govorun VM, Ilina EN. Shifts in the Human Gut Microbiota Structure Caused by Quadruple Helicobacter pylori Eradication Therapy. Front Microbiol 2019;10:1902. [PMID: 31507546 DOI: 10.3389/fmicb.2019.01902] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
175 Gemikonakli G, Mach J, Hilmer SN. Interactions Between the Aging Gut Microbiome and Common Geriatric Giants: Polypharmacy, Frailty, and Dementia. J Gerontol A Biol Sci Med Sci 2021;76:1019-28. [PMID: 32064521 DOI: 10.1093/gerona/glaa047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
176 Uchiyama AAT, Silva PAIA, Lopes MSM, Yen CT, Ricardo ED, Mutão T, Pimenta JR, Machado LM, Shimba DS, Peixoto RD. Proton Pump Inhibitors and Oncologic Treatment Efficacy: A Practical Review of the Literature for Oncologists. Curr Oncol 2021;28:783-99. [PMID: 33546228 DOI: 10.3390/curroncol28010076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
177 Cui X, Ye L, Li J, Jin L, Wang W, Li S, Bao M, Wu S, Li L, Geng B, Zhou X, Zhang J, Cai J. Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep 2018;8:635. [PMID: 29330424 DOI: 10.1038/s41598-017-18756-2] [Cited by in Crossref: 99] [Cited by in F6Publishing: 89] [Article Influence: 24.8] [Reference Citation Analysis]
178 Kawar N, Park SG, Schwartz JL, Callahan N, Obrez A, Yang B, Chen Z, Adami GR. Salivary microbiome with gastroesophageal reflux disease and treatment. Sci Rep 2021;11:188. [PMID: 33420219 DOI: 10.1038/s41598-020-80170-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Gantuya B, El-Serag HB, Matsumoto T, Ajami NJ, Oyuntsetseg K, Azzaya D, Uchida T, Yamaoka Y. Gastric Microbiota in Helicobacter pylori-Negative and -Positive Gastritis Among High Incidence of Gastric Cancer Area. Cancers (Basel). 2019;11. [PMID: 30974798 DOI: 10.3390/cancers11040504] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
180 Gaucher L, Adda L, Séjourné A, Joachim C, Guillaume C, Poulet C, Liabeuf S, Gras-Champel V, Masmoudi K, Houessinon A, Bennis Y, Batteux B. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol 2021;13:17588359211000591. [PMID: 33796151 DOI: 10.1177/17588359211000591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 De Bruyne P, Ito S. Toxicity of long-term use of proton pump inhibitors in children. Arch Dis Child 2017;103:78-82. [DOI: 10.1136/archdischild-2017-314026] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
182 Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, Guan XM, Cui YN, Su W. Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China. Dig Dis Sci 2019;64:1193-203. [PMID: 30535886 DOI: 10.1007/s10620-018-5411-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
183 Sinha R, Ahsan H, Blaser M, Caporaso JG, Carmical JR, Chan AT, Fodor A, Gail MH, Harris CC, Helzlsouer K, Huttenhower C, Knight R, Kong HH, Lai GY, Hutchinson DLS, Le Marchand L, Li H, Orlich MJ, Shi J, Truelove A, Verma M, Vogtmann E, White O, Willett W, Zheng W, Mahabir S, Abnet C. Next steps in studying the human microbiome and health in prospective studies, Bethesda, MD, May 16-17, 2017. Microbiome 2018;6:210. [PMID: 30477563 DOI: 10.1186/s40168-018-0596-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
184 Rindom Krogsgaard L, Kristian Munck L, Bytzer P, Wildt S. An altered composition of the microbiome in microscopic colitis is driven towards the composition in healthy controls by treatment with budesonide. Scandinavian Journal of Gastroenterology 2019;54:446-52. [DOI: 10.1080/00365521.2019.1599064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
185 Nkansa-Gyamfi NA, Kazibwe J, Traore DAK, Nji E. Prevalence of multidrug-, extensive drug-, and pandrug-resistant commensal Escherichia coli isolated from healthy humans in community settings in low- and middle-income countries: a systematic review and meta-analysis. Glob Health Action 2019;12:1815272. [PMID: 32909519 DOI: 10.1080/16549716.2020.1815272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
186 Dietert RR. Microbiome First Medicine in Health and Safety. Biomedicines 2021;9:1099. [PMID: 34572284 DOI: 10.3390/biomedicines9091099] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
188 Faleck DM, Salmasian H, Furuya EY, Larson EL, Abrams JA, Freedberg DE. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit. Am J Gastroenterol. 2016;111:1641-1648. [PMID: 27575714 DOI: 10.1038/ajg.2016.343] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
189 Kinashi Y, Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunol 2021;12:673708. [PMID: 33968085 DOI: 10.3389/fimmu.2021.673708] [Reference Citation Analysis]
190 Chan GC, Wong SH, Ng JK, Li PK, Szeto CC, Chow KM. Risk of peritonitis after gastroscopy in peritoneal dialysis patients. Perit Dial Int 2021;:8968608211018608. [PMID: 34032173 DOI: 10.1177/08968608211018608] [Reference Citation Analysis]
191 Jagdish BR, Kilgore WR 3rd. The Relationship Between Functional Dyspepsia, PPI Therapy, and the Gastric Microbiome. Kans J Med 2021;14:136-40. [PMID: 34084274 DOI: 10.17161/kjm.vol1414831] [Reference Citation Analysis]
192 Rashidi A, Ebadi M, Rehman TU, Elhusseini H, Nalluri H, Kaiser T, Holtan SG, Khoruts A, Weisdorf DJ, Staley C. Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome 2021;9:211. [PMID: 34702350 DOI: 10.1186/s40168-021-01170-2] [Reference Citation Analysis]
193 Andrianova NV, Popkov VA, Klimenko NS, Tyakht AV, Baydakova GV, Frolova OY, Zorova LD, Pevzner IB, Zorov DB, Plotnikov EY. Microbiome-Metabolome Signature of Acute Kidney Injury. Metabolites 2020;10:E142. [PMID: 32260384 DOI: 10.3390/metabo10040142] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
194 Hara T, Taniguchi M, Hattori C, Sakai H, Oka K, Iwai N, Tsuji T, Harada T, Okuda T, Komaki T, Sakagami J, Kagawa K. Microbiological analysis of patients with first and recurrent episodes of acute cholangitis in a middle-sized hospital: A single-center retrospective study in rural North Kyoto, Japan. J Infect Chemother 2021:S1341-321X(21)00336-6. [PMID: 34973874 DOI: 10.1016/j.jiac.2021.11.025] [Reference Citation Analysis]
195 Mücke MM, Rüschenbaum S, Mayer A, Mücke VT, Schwarzkopf KM, Zeuzem S, Kehrmann J, Scholtysik R, Lange CM. Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study. Gut Pathog 2020;12:51. [PMID: 33133240 DOI: 10.1186/s13099-020-00389-y] [Reference Citation Analysis]
196 Duque-Buitrago LF, Tornero-Martínez A, Loera-Castañeda V, Mora-Escobedo R. Use of food and food-derived products in the treatment of gastritis: A systematic review. Crit Rev Food Sci Nutr 2022;:1-12. [PMID: 34989280 DOI: 10.1080/10408398.2021.2024131] [Reference Citation Analysis]
197 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
198 Adelman MW, Woodworth MH, Langelier C, Busch LM, Kempker JA, Kraft CS, Martin GS. The gut microbiome's role in the development, maintenance, and outcomes of sepsis. Crit Care 2020;24:278. [PMID: 32487252 DOI: 10.1186/s13054-020-02989-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
199 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
200 Kielt MJ, Ferrara M, Shepherd EG. Striving to be better: medication overexposure among infants with severe BPD. J Perinatol 2019;39:1157-8. [DOI: 10.1038/s41372-019-0459-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
201 Barton W, O'Sullivan O, Cotter PD. Metabolic phenotyping of the human microbiome. F1000Res 2019;8:F1000 Faculty Rev-1956. [PMID: 31824656 DOI: 10.12688/f1000research.19481.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
202 Yde Aagaard ME, Frahm Kirk K, Linde Nielsen H, Harder Tarpgaard I, Bach Hansen J, Nielsen H. Campylobacter concisus is prevalent in the gastrointestinal tract of patients with microscopic colitis. Scand J Gastroenterol 2020;55:924-30. [PMID: 32667235 DOI: 10.1080/00365521.2020.1792976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
203 Lee KA, Shaw H, Bataille V, Nathan P. Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity. J Immunother Cancer 2020;8:e000577. [PMID: 33020237 DOI: 10.1136/jitc-2020-000577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
204 Tsai CF, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. Gastroenterology. 2017;152:134-141. [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
205 Chen L, Collij V, Jaeger M, van den Munckhof ICL, Vich Vila A, Kurilshikov A, Gacesa R, Sinha T, Oosting M, Joosten LAB, Rutten JHW, Riksen NP, Xavier RJ, Kuipers F, Wijmenga C, Zhernakova A, Netea MG, Weersma RK, Fu J. Gut microbial co-abundance networks show specificity in inflammatory bowel disease and obesity. Nat Commun 2020;11:4018. [PMID: 32782301 DOI: 10.1038/s41467-020-17840-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
206 Wirbel J, Zych K, Essex M, Karcher N, Kartal E, Salazar G, Bork P, Sunagawa S, Zeller G. Microbiome meta-analysis and cross-disease comparison enabled by the SIAMCAT machine learning toolbox. Genome Biol 2021;22:93. [PMID: 33785070 DOI: 10.1186/s13059-021-02306-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
207 Hsu BB, Plant IN, Lyon L, Anastassacos FM, Way JC, Silver PA. In situ reprogramming of gut bacteria by oral delivery. Nat Commun 2020;11:5030. [PMID: 33024097 DOI: 10.1038/s41467-020-18614-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
208 Le Bastard Q, Javaudin F, Montassier E. [Non-antibiotic drugs have large effect on the intestinal microbiota]. Med Sci (Paris) 2018;34:654-6. [PMID: 30230456 DOI: 10.1051/medsci/20183408008] [Reference Citation Analysis]
209 Pereira-Marques J, Ferreira RM, Pinto-Ribeiro I, Figueiredo C. Helicobacter pylori Infection, the Gastric Microbiome and Gastric Cancer. Adv Exp Med Biol 2019;1149:195-210. [PMID: 31016631 DOI: 10.1007/5584_2019_366] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
210 Cunningham R, Jones L, Enki DG, Tischhauser R. Proton pump inhibitor use as a risk factor for Enterobacteriaceal infection: a case-control study. J Hosp Infect 2018;100:60-4. [PMID: 29864485 DOI: 10.1016/j.jhin.2018.05.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
211 Allin KH, Moayyedi P. Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander? Gastroenterology 2021:S0016-5085(21)03478-8. [PMID: 34499912 DOI: 10.1053/j.gastro.2021.09.005] [Reference Citation Analysis]
212 Mohajeri MH, Brummer RJM, Rastall RA, Weersma RK, Harmsen HJM, Faas M, Eggersdorfer M. The role of the microbiome for human health: from basic science to clinical applications. Eur J Nutr 2018;57:1-14. [PMID: 29748817 DOI: 10.1007/s00394-018-1703-4] [Cited by in Crossref: 108] [Cited by in F6Publishing: 93] [Article Influence: 36.0] [Reference Citation Analysis]
213 Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: What if the results are true? Cancer Epidemiology 2018;54:139-40. [DOI: 10.1016/j.canep.2018.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
214 Di Paola M, Cavalieri D, Albanese D, Sordo M, Pindo M, Donati C, Pagnini I, Giani T, Simonini G, Paladini A, Lionetti P, De Filippo C, Cimaz R. Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status. Front Microbiol. 2016;7:1703. [PMID: 27833598 DOI: 10.3389/fmicb.2016.01703] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
215 Yaron JR, Ambadapadi S, Zhang L, Chavan RN, Tibbetts SA, Keinan S, Varsani A, Maldonado J, Kraberger S, Tafoya AM, Bullard WL, Kilbourne J, Stern-Harbutte A, Krajmalnik-Brown R, Munk BH, Koppang EO, Lim ES, Lucas AR. Immune protection is dependent on the gut microbiome in a lethal mouse gammaherpesviral infection. Sci Rep 2020;10:2371. [PMID: 32047224 DOI: 10.1038/s41598-020-59269-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
216 Hsu P, Pan C, Kao JY, Tsay F, Peng N, Kao S, Chen Y, Tsai T, Wu D, Tsai K. Short‐term and long‐term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. Journal of Gastroenterology and Hepatology 2019;34:1968-76. [DOI: 10.1111/jgh.14736] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
217 Huang X, Li M, Hou S, Tian B. Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review). Int J Oncol 2021;59:101. [PMID: 34738624 DOI: 10.3892/ijo.2021.5281] [Reference Citation Analysis]
218 Giustini N, Bazhenova L. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs). Lung Cancer (Auckl) 2021;12:21-34. [PMID: 33790679 DOI: 10.2147/LCTT.S235102] [Reference Citation Analysis]
219 Pasolli E, Truong DT, Malik F, Waldron L, Segata N. Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights. PLoS Comput Biol. 2016;12:e1004977. [PMID: 27400279 DOI: 10.1371/journal.pcbi.1004977] [Cited by in Crossref: 215] [Cited by in F6Publishing: 156] [Article Influence: 35.8] [Reference Citation Analysis]
220 Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, Wettermark B, Ärnlöv J, Janmaat CJ, Lindholm B, Dekker FW, Coresh J, Grams ME, Carrero JJ. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology 2017;153:702-10. [PMID: 28583827 DOI: 10.1053/j.gastro.2017.05.046] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 13.8] [Reference Citation Analysis]
221 Foster KR, Schluter J, Coyte KZ, Rakoff-Nahoum S. The evolution of the host microbiome as an ecosystem on a leash. Nature 2017;548:43-51. [PMID: 28770836 DOI: 10.1038/nature23292] [Cited by in Crossref: 328] [Cited by in F6Publishing: 257] [Article Influence: 65.6] [Reference Citation Analysis]
222 Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739. [PMID: 29084798 DOI: 10.1136/bmjopen-2017-017739] [Cited by in Crossref: 85] [Cited by in F6Publishing: 75] [Article Influence: 17.0] [Reference Citation Analysis]
223 Jackson MA, Verdi S, Maxan ME, Shin CM, Zierer J, Bowyer RCE, Martin T, Williams FMK, Menni C, Bell JT, Spector TD, Steves CJ. Gut microbiota associations with common diseases and prescription medications in a population-based cohort. Nat Commun 2018;9:2655. [PMID: 29985401 DOI: 10.1038/s41467-018-05184-7] [Cited by in Crossref: 185] [Cited by in F6Publishing: 165] [Article Influence: 46.3] [Reference Citation Analysis]
224 Savarino EV, Iovino P, Santonicola A, Ghisa M, Laserra G, Barberio B, Maniero D, Lorenzon G, Ciacci C, Savarino V, Zingone F. Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. J Clin Med 2020;9:E2011. [PMID: 32604895 DOI: 10.3390/jcm9062011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
225 van Hemert S, Skonieczna-Żydecka K, Loniewski I, Szredzki P, Marlicz W. Microscopic colitis-microbiome, barrier function and associated diseases. Ann Transl Med 2018;6:39. [PMID: 29610731 DOI: 10.21037/atm.2017.03.83] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
226 Laforest-Lapointe I, Arrieta MC. Patterns of Early-Life Gut Microbial Colonization during Human Immune Development: An Ecological Perspective. Front Immunol 2017;8:788. [PMID: 28740492 DOI: 10.3389/fimmu.2017.00788] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 13.4] [Reference Citation Analysis]
227 Reveles KR, Ryan CN, Chan L, Cosimi RA, Haynes WL. Proton pump inhibitor use associated with changes in gut microbiota composition. Gut 2018;67:1369-70. [PMID: 28993417 DOI: 10.1136/gutjnl-2017-315306] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
228 Kellerer T, Brandl B, Büttner J, Lagkouvardos I, Hauner H, Skurk T. Impact of Laparoscopic Sleeve Gastrectomy on Gut Permeability in Morbidly Obese Subjects. Obes Surg 2019;29:2132-43. [PMID: 30903427 DOI: 10.1007/s11695-019-03815-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
229 Kuo CJ, Lin CY, Chen CW, Hsu CY, Hsieh SY, Chiu CT, Lin WR. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study. J Pers Med 2021;11:1063. [PMID: 34834415 DOI: 10.3390/jpm11111063] [Reference Citation Analysis]
230 Schubert ML. Physiologic, pathophysiologic, and pharmacologic regulation of gastric acid secretion. Current Opinion in Gastroenterology 2017;33:430-8. [DOI: 10.1097/mog.0000000000000392] [Cited by in Crossref: 25] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
231 Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, van Putten SAW, Taxis K, Borgsteede SD. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84:1806-1820. [PMID: 29688583 DOI: 10.1111/bcp.13615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
232 Meijer LL, Zwart ES, Brandt BW, Mebius R, Deng D, Giovannetti E, Zaura E, Kazemier G. Tumor microbiome: Pancreatic cancer and duodenal fluids contain multitudes, …but do they contradict themselves? Crit Rev Oncol Hematol 2019;144:102824. [PMID: 31731215 DOI: 10.1016/j.critrevonc.2019.102824] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
233 Wu Y, Du S, Johnson JL, Tung HY, Landers CT, Liu Y, Seman BG, Wheeler RT, Costa-Mattioli M, Kheradmand F, Zheng H, Corry DB. Microglia and amyloid precursor protein coordinate control of transient Candida cerebritis with memory deficits. Nat Commun 2019;10:58. [PMID: 30610193 DOI: 10.1038/s41467-018-07991-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
234 Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis. 2020;52:842-852. [PMID: 32513631 DOI: 10.1016/j.dld.2020.04.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
235 DeClercq V, Nearing JT, Langille MGI. Investigation of the impact of commonly used medications on the oral microbiome of individuals living without major chronic conditions. PLoS One 2021;16:e0261032. [PMID: 34882708 DOI: 10.1371/journal.pone.0261032] [Reference Citation Analysis]
236 Iino C, Shimoyama T, Chinda D, Arai T, Chiba D, Nakaji S, Fukuda S. Infection of Helicobacter pylori and Atrophic Gastritis Influence Lactobacillus in Gut Microbiota in a Japanese Population. Front Immunol. 2018;9:712. [PMID: 29681906 DOI: 10.3389/fimmu.2018.00712] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
237 Maeda S, Yamaguchi M, Maeda K, Kobayashi N, Izumi N, Nagai M, Obayashi T, Ohashi W, Katsuno T, Nobata H, Ito Y. Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. PLoS One 2019;14:e0224859. [PMID: 31697753 DOI: 10.1371/journal.pone.0224859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
238 Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, Markó L, Aron-Wisnewsky J, Nielsen T, Moitinho-Silva L, Schmidt TSB, Falony G, Vieira-Silva S, Adriouch S, Alves RJ, Assmann K, Bastard JP, Birkner T, Caesar R, Chilloux J, Coelho LP, Fezeu L, Galleron N, Helft G, Isnard R, Ji B, Kuhn M, Le Chatelier E, Myridakis A, Olsson L, Pons N, Prifti E, Quinquis B, Roume H, Salem JE, Sokolovska N, Tremaroli V, Valles-Colomer M, Lewinter C, Søndertoft NB, Pedersen HK, Hansen TH, Gøtze JP, Køber L, Vestergaard H, Hansen T, Zucker JD, Hercberg S, Oppert JM, Letunic I, Nielsen J, Bäckhed F, Ehrlich SD, Dumas ME, Raes J, Pedersen O, Clément K, Stumvoll M, Bork P; MetaCardis Consortium*. Combinatorial, additive and dose-dependent drug-microbiome associations. Nature 2021;600:500-5. [PMID: 34880489 DOI: 10.1038/s41586-021-04177-9] [Reference Citation Analysis]
239 Jarett JK, Kingsbury DD, Dahlhausen KE, Ganz HH. Best Practices for Microbiome Study Design in Companion Animal Research. Front Vet Sci 2021;8:644836. [PMID: 33898544 DOI: 10.3389/fvets.2021.644836] [Reference Citation Analysis]
240 Ihekweazu FD, Versalovic J. Development of the Pediatric Gut Microbiome: Impact on Health and Disease. Am J Med Sci 2018;356:413-23. [PMID: 30384950 DOI: 10.1016/j.amjms.2018.08.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
241 Zhang X, Han Y, Huang W, Jin M, Gao Z. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B 2021;11:1789-812. [PMID: 34386321 DOI: 10.1016/j.apsb.2020.09.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Dietert RR. Safety and risk assessment for the human superorganism. Human and Ecological Risk Assessment: An International Journal 2017;23:1819-29. [DOI: 10.1080/10807039.2017.1356683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 He C, Peng C, Wang H, Ouyang Y, Zhu Z, Shu X, Zhu Y, Lu N. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults. Helicobacter 2019. [DOI: 10.1111/hel.12590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
244 Lenoir C, El Biali M, Luthy C, Grosgurin O, Desmeules JA, Rollason V. Snapshot of proton pump inhibitors prescriptions in a tertiary care hospital in Switzerland: less is more? Int J Clin Pharm 2019;41:1634-41. [DOI: 10.1007/s11096-019-00929-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
245 Singh A, Garg R, Lan N, Siddiqui MT, Gupta M, Alkhouri N. Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:591-8. [DOI: 10.1007/s12664-020-01087-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Khalili H, Axelrad JE, Roelstraete B, Olén O, D'Amato M, Ludvigsson JF. Gastrointestinal Infection and Risk of Microscopic Colitis: A Nationwide Case-Control Study in Sweden. Gastroenterology 2021;160:1599-1607.e5. [PMID: 33421519 DOI: 10.1053/j.gastro.2021.01.004] [Reference Citation Analysis]
247 Cetin H, Wurm R, Reichardt B, Tomschik M, Silvaieh S, Parvizi T, König T, Erber A, Schernhammer E, Stamm T, Stögmann E. Increased risk of death associated with the use of proton-pump inhibitors in patients with dementia and controls - a pharmacoepidemiological claims data analysis. Eur J Neurol 2020;27:1422-8. [PMID: 32281706 DOI: 10.1111/ene.14252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Horvath A, Rainer F, Bashir M, Leber B, Schmerboeck B, Klymiuk I, Groselj-Strele A, Durdevic M, Freedberg DE, Abrams JA, Fickert P, Stiegler P, Stadlbauer V. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep. 2019;9:12000. [PMID: 31427714 DOI: 10.1038/s41598-019-48352-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
249 Richards J. Manipulating microbiomes: Present and future perspective. Clin Exp Ophthalmol 2019;47:315-6. [PMID: 31016857 DOI: 10.1111/ceo.13508] [Reference Citation Analysis]
250 Wauters L, Burns G, Ceulemans M, Walker MM, Vanuytsel T, Keely S, Talley NJ. Duodenal inflammation: an emerging target for functional dyspepsia? Expert Opin Ther Targets 2020;24:511-23. [PMID: 32249629 DOI: 10.1080/14728222.2020.1752181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
251 Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
252 Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M, Griffin BT, Grimm M, Keszthelyi D, Koziolek M, Madla CM, Matthys C, McCoubrey LE, Mitra A, Reppas C, Stappaerts J, Steenackers N, Trevaskis NL, Vanuytsel T, Vertzoni M, Weitschies W, Wilson C, Augustijns P. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci 2021;162:105812. [PMID: 33753215 DOI: 10.1016/j.ejps.2021.105812] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
253 Douwes RM, Gomes-Neto AW, Eisenga MF, Van Loon E, Schutten JC, Gans ROB, Naesens M, van den Berg E, Sprangers B, Berger SP, Navis G, Blokzijl H, Meijers B, Bakker SJL, Kuypers D. The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. PLoS Med 2020;17:e1003140. [PMID: 32542023 DOI: 10.1371/journal.pmed.1003140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Rosenberg V, Tzadok R, Chodick G, Kariv R. Proton pump inhibitors long term use-trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiol Drug Saf 2021;30:1576-87. [PMID: 34453456 DOI: 10.1002/pds.5352] [Reference Citation Analysis]
255 Hung T, Lee H, Tseng C, Tsai C, Tsai C. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clinics and Research in Hepatology and Gastroenterology 2018;42:353-9. [DOI: 10.1016/j.clinre.2017.11.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
256 Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol 2020;55:453-61. [PMID: 31811561 DOI: 10.1007/s00535-019-01652-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
257 Bajaj JS, Acharya C, Fagan A, White MB, Gavis E, Heuman DM, Hylemon PB, Fuchs M, Puri P, Schubert ML, Sanyal AJ, Sterling RK, Stravitz TR, Siddiqui MS, Luketic V, Lee H, Sikaroodi M, Gillevet PM. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis. Am J Gastroenterol. 2018;113:1177-1186. [PMID: 29872220 DOI: 10.1038/s41395-018-0085-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 14.5] [Reference Citation Analysis]
258 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
259 Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of colorectal cancer. Gut 2021:gutjnl-2021-325096. [PMID: 34210775 DOI: 10.1136/gutjnl-2021-325096] [Reference Citation Analysis]
260 Lin YT, Lin TY, Hung SC, Liu PY, Wu PH, Chuang YS, Hung WC, Chiu YW, Kuo MC, Wu CY. Anti-Acid Drug Treatment Induces Changes in the Gut Microbiome Composition of Hemodialysis Patients. Microorganisms 2021;9:286. [PMID: 33573326 DOI: 10.3390/microorganisms9020286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
261 Wang D, Hao H, Li X, Wang Z. The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: a narrative review. Ann Transl Med 2020;8:1097. [PMID: 33145316 DOI: 10.21037/atm-20-4535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
262 Shi YC, Cai ST, Tian YP, Zhao HJ, Zhang YB, Chen J, Ren RR, Luo X, Peng LH, Sun G, Yang YS. Effects of Proton Pump Inhibitors on the Gastrointestinal Microbiota in Gastroesophageal Reflux Disease. Genomics Proteomics Bioinformatics 2019;17:52-63. [PMID: 31028880 DOI: 10.1016/j.gpb.2018.12.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
263 Van Wilpe S, Koornstra R, Den Brok M, De Groot JW, Blank C, De Vries J, Gerritsen W, Mehra N. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology 2020;9:1731942. [PMID: 32158624 DOI: 10.1080/2162402X.2020.1731942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
264 Weltermann T, Schulz C, Macke L. Effect of frequently prescribed drugs on gastric cancer risk. Best Pract Res Clin Gastroenterol 2021;50-51:101741. [PMID: 33975680 DOI: 10.1016/j.bpg.2021.101741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
265 Yuan J, He Q, Nguyen LH, Wong MCS, Huang J, Yu Y, Xia B, Tang Y, He Y, Zhang C. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut 2021;70:1070-7. [PMID: 32989021 DOI: 10.1136/gutjnl-2020-322557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
266 van der Meulen T, Harmsen H, Bootsma H, Spijkervet F, Kroese F, Vissink A. The microbiome-systemic diseases connection. Oral Dis 2016;22:719-34. [DOI: 10.1111/odi.12472] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 9.3] [Reference Citation Analysis]
267 Caparrós-Martín JA, Lareu RR, Ramsay JP, Peplies J, Reen FJ, Headlam HA, Ward NC, Croft KD, Newsholme P, Hughes JD, O'Gara F. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 2017;5:95. [PMID: 28793934 DOI: 10.1186/s40168-017-0312-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 14.0] [Reference Citation Analysis]
268 Boban M, Zulj M, Persic V, Medved I, Zekanovic D, Vcev A. Prolonged utilization of proton pump inhibitors in patients with ischemic and valvular heart disease is associated with surgical treatments, weight loss and aggravates anemia. Int J Cardiol 2016;219:277-81. [PMID: 27343420 DOI: 10.1016/j.ijcard.2016.06.058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
269 Le Bastard Q, Berthelot L, Soulillou JP, Montassier E. Impact of non-antibiotic drugs on the human intestinal microbiome. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34225544 DOI: 10.1080/14737159.2021.1952075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 2021;10:18. [PMID: 33653420 DOI: 10.1186/s40164-021-00211-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
271 Nadatani Y, Watanabe T, Suda W, Nakata A, Matsumoto Y, Kosaka S, Higashimori A, Otani K, Hosomi S, Tanaka F, Nagami Y, Kamata N, Taira K, Yamagami H, Tanigawa T, Hattori M, Fujiwara Y. Gastric acid inhibitor aggravates indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii. Sci Rep 2019;9:17490. [PMID: 31767915 DOI: 10.1038/s41598-019-53559-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
272 Koidl L, Untersmayr E. The clinical implications of the microbiome in the development of allergy diseases. Expert Rev Clin Immunol 2021;17:115-26. [PMID: 33428498 DOI: 10.1080/1744666X.2021.1874353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Li DK, Chung RT. Use of proton pump inhibitors in chronic liver diseases. Clin Liver Dis (Hoboken) 2017;10:148-51. [PMID: 30992776 DOI: 10.1002/cld.678] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
274 Erber AC, Cetin H, Berry D, Schernhammer ES. The role of gut microbiota, butyrate and proton pump inhibitors in amyotrophic lateral sclerosis: a systematic review. Int J Neurosci 2020;130:727-35. [PMID: 31870202 DOI: 10.1080/00207454.2019.1702549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
275 Mukherjee S, Ibrahimi S, Khalid B, Roman D, Zhao D, Aljumaily R. Do proton pump inhibitors modulate the efficacy of anti-PD-1/PD-L1 therapy? A retrospective study. J Oncol Pharm Pract 2019;25:762-4. [PMID: 29690815 DOI: 10.1177/1078155218771152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
276 Raffelsberger N, Hetland MAK, Svendsen K, Småbrekke L, Löhr IH, Andreassen LLE, Brisse S, Holt KE, Sundsfjord A, Samuelsen Ø, Gravningen K. Gastrointestinal carriage of Klebsiella pneumoniae in a general adult population: a cross-sectional study of risk factors and bacterial genomic diversity. Gut Microbes 2021;13:1939599. [PMID: 34182896 DOI: 10.1080/19490976.2021.1939599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
277 Maharshak N, Cohen NA, Reshef L, Tulchinsky H, Gophna U, Dotan I. Alterations of Enteric Microbiota in Patients with a Normal Ileal Pouch Are Predictive of Pouchitis. J Crohns Colitis 2017;11:314-20. [PMID: 27613294 DOI: 10.1093/ecco-jcc/jjw157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
278 Wurm P, Dörner E, Kremer C, Spranger J, Maddox C, Halwachs B, Harrison U, Blanchard T, Haas R, Högenauer C, Gorkiewicz G, Fricke WF. Qualitative and Quantitative DNA- and RNA-Based Analysis of the Bacterial Stomach Microbiota in Humans, Mice, and Gerbils. mSystems 2018;3:e00262-18. [PMID: 30505943 DOI: 10.1128/mSystems.00262-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
279 Koliarakis I, Messaritakis I, Nikolouzakis TK, Hamilos G, Souglakos J, Tsiaoussis J. Oral Bacteria and Intestinal Dysbiosis in Colorectal Cancer. Int J Mol Sci 2019;20:E4146. [PMID: 31450675 DOI: 10.3390/ijms20174146] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 13.0] [Reference Citation Analysis]
280 Mullane KM, Dubberke ER; AST ID Community of Practice. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant 2019;33:e13564. [PMID: 31002420 DOI: 10.1111/ctr.13564] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
281 Stokes AL, Bible A, Hollenbeak CS, Stewart DB Sr. Clostridium difficile Infection Is Associated With Lower Inpatient Mortality When Managed by GI Surgeons. Dis Colon Rectum 2016;59:855-61. [PMID: 27505114 DOI: 10.1097/DCR.0000000000000643] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
282 Horvath A, Leber B, Feldbacher N, Steinwender M, Komarova I, Rainer F, Blesl A, Stadlbauer V. The effects of a multispecies synbiotic on microbiome-related side effects of long-term proton pump inhibitor use: A pilot study. Sci Rep 2020;10:2723. [PMID: 32066847 DOI: 10.1038/s41598-020-59550-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
283 Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, Matsumoto K, Asaoka D, Takahashi T, Nomoto K, Yamashiro Y, Watanabe S. Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors. Dig Dis Sci. 2018;63:2940-2949. [PMID: 29796911 DOI: 10.1007/s10620-018-5122-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
284 Craig SJC, Blankenberg D, Parodi ACL, Paul IM, Birch LL, Savage JS, Marini ME, Stokes JL, Nekrutenko A, Reimherr M, Chiaromonte F, Makova KD. Child Weight Gain Trajectories Linked To Oral Microbiota Composition. Sci Rep 2018;8:14030. [PMID: 30232389 DOI: 10.1038/s41598-018-31866-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
285 Czarniak P, Ahmadizar F, Hughes J, Parsons R, Kavousi M, Ikram M, Stricker BH. Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population-based cohort study. Br J Clin Pharmacol 2021. [PMID: 34907592 DOI: 10.1111/bcp.15182] [Reference Citation Analysis]
286 Gustot T, Stadlbauer V, Laleman W, Alessandria C, Thursz M. Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events. J Hepatol 2021;75 Suppl 1:S36-48. [PMID: 34039491 DOI: 10.1016/j.jhep.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
287 Dziechciarz P, Krenke K, Szajewska H, Horvath A. Lactobacillus rhamnosus GG Usage in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children with Gastroesophageal Reflux Disease Treated with Proton Pump Inhibitors: A Randomized Double-Blinded Placebo-Controlled Trial. Pediatr Gastroenterol Hepatol Nutr 2020;23:251-8. [PMID: 32483546 DOI: 10.5223/pghn.2020.23.3.251] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
288 Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut 2021:gutjnl-2021-325097. [PMID: 34226290 DOI: 10.1136/gutjnl-2021-325097] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Patel PJ, Hayward KL, Rudra R, Horsfall LU, Hossain F, Williams S, Johnson T, Brown NN, Saad N, Clouston AD, Stuart KA, Valery PC, Irvine KM, Russell AW, Powell EE. Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management. Medicine (Baltimore) 2017;96:e6761. [PMID: 28658094 DOI: 10.1097/MD.0000000000006761] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
290 Nardelli C, Granata I, D'Argenio V, Tramontano S, Compare D, Guarracino MR, Nardone G, Pilone V, Sacchetti L. Characterization of the Duodenal Mucosal Microbiome in Obese Adult Subjects by 16S rRNA Sequencing. Microorganisms 2020;8:E485. [PMID: 32235377 DOI: 10.3390/microorganisms8040485] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
291 Ibáñez-Sanz G, Milà N, de la Peña-Negro LC, Garcia M, Vidal C, Rodríguez-Alonso L, Binefa G, Rodríguez-Moranta F, Moreno V. Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing. J Gastroenterol 2021;56:42-53. [PMID: 33159805 DOI: 10.1007/s00535-020-01738-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
292 Doohan D, Rezkitha YAA, Waskito LA, Vilaichone R, Yamaoka Y, Miftahussurur M. Integrating microbiome, transcriptome and metabolome data to investigate gastric disease pathogenesis: a concise review. Expert Rev Mol Med 2021;23. [DOI: 10.1017/erm.2021.8] [Reference Citation Analysis]
293 Ding JH, Jin Z, Yang XX, Lou J, Shan WX, Hu YX, Du Q, Liao QS, Xie R, Xu JY. Role of gut microbiota via the gut-liver-brain axis in digestive diseases. World J Gastroenterol 2020; 26(40): 6141-6162 [PMID: 33177790 DOI: 10.3748/wjg.v26.i40.6141] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
294 Frau A, Ijaz UZ, Slater R, Jonkers D, Penders J, Campbell BJ, Kenny JG, Hall N, Lenzi L, Burkitt MD, Pierik M, Darby AC, Probert CSJ. Inter-kingdom relationships in Crohn's disease explored using a multi-omics approach. Gut Microbes 2021;13:1930871. [PMID: 34241567 DOI: 10.1080/19490976.2021.1930871] [Reference Citation Analysis]
295 Nycz J, Zajdel A. Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii. Postępy Higieny i Medycyny Doświadczalnej 2021;75:762-72. [DOI: 10.2478/ahem-2021-0009] [Reference Citation Analysis]
296 Mougey EB, Nguyen V, Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, Rayo A, Borrell B, Román E, González-Lois C, Chao M, Al-Atrash H, Franciosi JP. STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-term Proton Pump Inhibitor Therapy. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31129-0. [PMID: 32798708 DOI: 10.1016/j.cgh.2020.08.020] [Reference Citation Analysis]
297 Shi D, Zhou Z, Dai Y, Pan X, Cao Q. Proton Pump Inhibitor Therapy and Hepatic Encephalopathy Risk in Cirrhotic Patients: A Systematic Review with Meta-analysis. Clin Drug Investig 2019;39:847-56. [DOI: 10.1007/s40261-019-00810-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
298 Danne C, Rolhion N, Sokol H. Recipient factors in faecal microbiota transplantation: one stool does not fit all. Nat Rev Gastroenterol Hepatol 2021;18:503-13. [PMID: 33907321 DOI: 10.1038/s41575-021-00441-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
299 Tanigawa T, Watanabe T, Higashimori A, Shimada S, Kitamura H, Kuzumoto T, Nadatani Y, Otani K, Fukunaga S, Hosomi S, Tanaka F, Kamata N, Nagami Y, Taira K, Shiba M, Suda W, Hattori M, Fujiwara Y. Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota. PLoS One 2021;16:e0245995. [PMID: 33507971 DOI: 10.1371/journal.pone.0245995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
300 Zimmermann M, Patil KR, Typas A, Maier L. Towards a mechanistic understanding of reciprocal drug-microbiome interactions. Mol Syst Biol 2021;17:e10116. [PMID: 33734582 DOI: 10.15252/msb.202010116] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
301 Van Ameringen M, Turna J, Patterson B, Pipe A, Mao RQ, Anglin R, Surette MG. The gut microbiome in psychiatry: A primer for clinicians. Depress Anxiety 2019;36:1004-25. [PMID: 31356715 DOI: 10.1002/da.22936] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
302 Wang Y, Wang H, Howard AG, Tsilimigras MCB, Avery CL, Meyer KA, Sha W, Sun S, Zhang J, Su C, Wang Z, Zhang B, Fodor AA, Gordon-Larsen P. Associations of sodium and potassium consumption with the gut microbiota and host metabolites in a population-based study in Chinese adults. Am J Clin Nutr 2020;112:1599-612. [PMID: 33022700 DOI: 10.1093/ajcn/nqaa263] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
303 Tu P, Chi L, Bodnar W, Zhang Z, Gao B, Bian X, Stewart J, Fry R, Lu K. Gut Microbiome Toxicity: Connecting the Environment and Gut Microbiome-Associated Diseases. Toxics 2020;8:E19. [PMID: 32178396 DOI: 10.3390/toxics8010019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
304 Wind TT, Gacesa R, Vich Vila A, de Haan JJ, Jalving M, Weersma RK, Hospers GAP. Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma. Melanoma Res 2020;30:235-46. [PMID: 31990790 DOI: 10.1097/CMR.0000000000000656] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
305 Wroblewski LE, Peek RM Jr, Coburn LA. The Role of the Microbiome in Gastrointestinal Cancer. Gastroenterol Clin North Am 2016;45:543-56. [PMID: 27546848 DOI: 10.1016/j.gtc.2016.04.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
306 Hansen TH, Thomassen MT, Madsen ML, Kern T, Bak EG, Kashani A, Allin KH, Hansen T, Pedersen O. The effect of drinking water pH on the human gut microbiota and glucose regulation: results of a randomized controlled cross-over intervention. Sci Rep 2018;8:16626. [PMID: 30413727 DOI: 10.1038/s41598-018-34761-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
307 Lagier J. Gut microbiota and Clostridium difficile infections. Human Microbiome Journal 2016;2:10-4. [DOI: 10.1016/j.humic.2016.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
308 Iino C, Shimoyama T. Impact of Helicobacter pylori infection on gut microbiota. World J Gastroenterol 2021; 27(37): 6224-6230 [PMID: 34712028 DOI: 10.3748/wjg.v27.i37.6224] [Reference Citation Analysis]
309 Wen L, Duffy A. Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J Nutr. 2017;147:1468S-1475S. [PMID: 28615382 DOI: 10.3945/jn.116.240754] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 25.2] [Reference Citation Analysis]
310 Kawashima R, Tamaki S, Kawakami F, Maekawa T, Ichikawa T. Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis. Int J Mol Sci 2020;21:E8166. [PMID: 33142910 DOI: 10.3390/ijms21218166] [Reference Citation Analysis]
311 Durán C, Ciucci S, Palladini A, Ijaz UZ, Zippo AG, Sterbini FP, Masucci L, Cammarota G, Ianiro G, Spuul P, Schroeder M, Grill SW, Parsons BN, Pritchard DM, Posteraro B, Sanguinetti M, Gasbarrini G, Gasbarrini A, Cannistraci CV. Nonlinear machine learning pattern recognition and bacteria-metabolite multilayer network analysis of perturbed gastric microbiome. Nat Commun 2021;12:1926. [PMID: 33771992 DOI: 10.1038/s41467-021-22135-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
312 Søgaard M, Heide-Jørgensen U, Vandenbroucke JP, Schønheyder HC, Vandenbroucke-Grauls CMJE. Risk factors for extended-spectrum β-lactamase-producing Escherichia coli urinary tract infection in the community in Denmark: a case-control study. Clin Microbiol Infect 2017;23:952-60. [PMID: 28377310 DOI: 10.1016/j.cmi.2017.03.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
313 Tabata T, Yamashita T, Hosomi K, Park J, Hayashi T, Yoshida N, Saito Y, Fukuzawa K, Konishi K, Murakami H, Kawashima H, Mizuguchi K, Miyachi M, Kunisawa J, Hirata KI. Gut microbial composition in patients with atrial fibrillation: effects of diet and drugs. Heart Vessels 2021;36:105-14. [PMID: 32683492 DOI: 10.1007/s00380-020-01669-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
314 Sbeit W, Khoury T, Kadah A, Asadi W, Shahin A, Lubany A, Safadi M, Haddad H, Abu Ahmad R, Abu El Hija S, Abboud R, Mahamid M, Pellicano R, Mari A. Proton Pump Inhibitor Use May Increase the Risk of Diverticulitis but Not It's Severity among Patients with Colonic Diverticulosis: A Multicenter Study. J Clin Med 2020;9:E2966. [PMID: 32937926 DOI: 10.3390/jcm9092966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
315 Kimura T, Snijder R, Sugitani T. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset. J Infect Chemother 2019;25:615-20. [PMID: 30987950 DOI: 10.1016/j.jiac.2019.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
316 Chen LA, Hourigan SK, Grigoryan Z, Gao Z, Clemente JC, Rideout JR, Chirumamilla S, Rabidazeh S, Saeed S, Elson CO, Oliva-Hemker M, Blaser MJ, Sears CL. Decreased Fecal Bacterial Diversity and Altered Microbiome in Children Colonized With Clostridium difficile. J Pediatr Gastroenterol Nutr 2019;68:502-8. [PMID: 30540709 DOI: 10.1097/MPG.0000000000002210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
317 Park H, Cho D, Huang E, Seo JY, Kim WG, Todorov SD, Ji Y, Holzapfel WH. Amelioration of Alcohol Induced Gastric Ulcers Through the Administration of Lactobacillus plantarum APSulloc 331261 Isolated From Green Tea. Front Microbiol 2020;11:420. [PMID: 32256476 DOI: 10.3389/fmicb.2020.00420] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
318 Imperatore N, Tortora R, Testa A, Gerbino N, Caporaso N, Rispo A. Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet. J Gastroenterol 2018;53:507-16. [DOI: 10.1007/s00535-017-1381-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
319 Schmidt TSB, Raes J, Bork P. The Human Gut Microbiome: From Association to Modulation. Cell 2018;172:1198-215. [PMID: 29522742 DOI: 10.1016/j.cell.2018.02.044] [Cited by in Crossref: 285] [Cited by in F6Publishing: 238] [Article Influence: 95.0] [Reference Citation Analysis]
320 Bradley ES, Howe E, Wu X, Haran JP. Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment. Gut Pathog 2019;11:29. [PMID: 31210787 DOI: 10.1186/s13099-019-0309-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
321 Zakrzewski M, Simms LA, Brown A, Appleyard M, Irwin J, Waddell N, Radford-Smith GL. IL23R-Protective Coding Variant Promotes Beneficial Bacteria and Diversity in the Ileal Microbiome in Healthy Individuals Without Inflammatory Bowel Disease. J Crohns Colitis 2019;13:451-61. [PMID: 30445599 DOI: 10.1093/ecco-jcc/jjy188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
322 Qin BD, Jiao XD, Zhou XC, Shi B, Wang J, Liu K, Wu Y, Ling Y, Zang YS. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer. Oncoimmunology 2021;10:1929727. [PMID: 34350061 DOI: 10.1080/2162402X.2021.1929727] [Reference Citation Analysis]
323 Lang JM, Pan C, Cantor RM, Tang WHW, Garcia-Garcia JC, Kurtz I, Hazen SL, Bergeron N, Krauss RM, Lusis AJ. Impact of Individual Traits, Saturated Fat, and Protein Source on the Gut Microbiome. mBio 2018;9:e01604-18. [PMID: 30538180 DOI: 10.1128/mBio.01604-18] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 7.8] [Reference Citation Analysis]
324 Pettigrew MM, Gent JF, Kong Y, Halpin AL, Pineles L, Harris AD, Johnson JK. Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients. Clin Infect Dis 2019;69:604-13. [PMID: 30383203 DOI: 10.1093/cid/ciy936] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
325 Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gillilland MG 3rd, Hayashi A, Imai J, Sugihara K, Miyoshi M, Brazil JC, Kuffa P, Hill BD, Rizvi SM, Wen F, Bishu S, Inohara N, Eaton KA, Nusrat A, Lei YL, Giannobile WV, Kamada N. The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis. Cell 2020;182:447-462.e14. [PMID: 32758418 DOI: 10.1016/j.cell.2020.05.048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 29.5] [Reference Citation Analysis]
326 Hakuta R, Nakai Y, Hamada T, Nomura Y, Saito T, Takahara N, Mizuno S, Kogure H, Moriya K, Koike K. Use of proton pump inhibitors and cholangitis complicated with multi-drug resistant bacteria. J Hepatobiliary Pancreat Sci 2021. [PMID: 34382333 DOI: 10.1002/jhbp.1035] [Reference Citation Analysis]
327 Pierrard J, Seront E. Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review. Curr Oncol 2019;26:395-403. [PMID: 31896938 DOI: 10.3747/co.26.5177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
328 Liang CS, Bai YM, Hsu JW, Huang KL, Ko NY, Tsai CK, Yeh TC, Chu HT, Tsai SJ, Chen TJ, Chen MH. The Risk of Epilepsy after Long-term Proton Pump Inhibitor Therapy. Seizure 2021;87:88-93. [PMID: 33735722 DOI: 10.1016/j.seizure.2021.03.008] [Reference Citation Analysis]
329 Wang J, Wu Y, Bi Q, Zheng X, Zhang J, Huang W. Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis. Hepatol Int 2020;14:385-98. [PMID: 31912308 DOI: 10.1007/s12072-019-10010-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
330 Jacobson JC, Pandya SR. A narrative review of gastroesophageal reflux in the pediatric patient. Transl Gastroenterol Hepatol 2021;6:34. [PMID: 34423155 DOI: 10.21037/tgh-20-245] [Reference Citation Analysis]
331 Hills RD Jr, Pontefract BA, Mishcon HR, Black CA, Sutton SC, Theberge CR. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients 2019;11:E1613. [PMID: 31315227 DOI: 10.3390/nu11071613] [Cited by in Crossref: 172] [Cited by in F6Publishing: 142] [Article Influence: 57.3] [Reference Citation Analysis]
332 Gommers LMM, Ederveen THA, van der Wijst J, Overmars-Bos C, Kortman GAM, Boekhorst J, Bindels RJM, de Baaij JHF, Hoenderop JGJ. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia. FASEB J 2019;33:11235-46. [PMID: 31299175 DOI: 10.1096/fj.201900839R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
333 Wu L, Wang Z, Sun G, Peng L, Lu Z, Yan B, Huang K, Yang Y. Effects of anti-H. pylori triple therapy and a probiotic complex on intestinal microbiota in duodenal ulcer. Sci Rep 2019;9:12874. [PMID: 31492912 DOI: 10.1038/s41598-019-49415-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
334 Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2018;. [PMID: 30289992 DOI: 10.1002/hep.30304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
335 Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.Int J Mol Sci. 2020;21. [PMID: 32046317 DOI: 10.3390/ijms21031136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
336 Newsome RC, Gauthier J, Hernandez MC, Abraham GE, Robinson TO, Williams HB, Sloan M, Owings A, Laird H, Christian T, Pride Y, Wilson KJ, Hasan M, Parker A, Senitko M, Glover SC, Gharaibeh RZ, Jobin C. The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort. Gut Microbes 2021;13:1-15. [PMID: 34100340 DOI: 10.1080/19490976.2021.1926840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Zheng YF, Liang SP, Zhong ZS, Zhang W, Wu YY, Liu JB, Huang SP. Duodenal microbiota makes an important impact in functional dyspepsia. Microb Pathog 2021;162:105297. [PMID: 34883227 DOI: 10.1016/j.micpath.2021.105297] [Reference Citation Analysis]
338 Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use: Proton pump inhibitors. Journal of Gastroenterology and Hepatology 2017;32:1295-302. [DOI: 10.1111/jgh.13737] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
339 Dogra SK, Doré J, Damak S. Gut Microbiota Resilience: Definition, Link to Health and Strategies for Intervention. Front Microbiol 2020;11:572921. [PMID: 33042082 DOI: 10.3389/fmicb.2020.572921] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
340 Chen WC, Lin KH, Huang YT, Tsai TJ, Sun WC, Chuah SK, Wu DC, Hsu PI. The risk of lower gastrointestinal bleeding in low-dose aspirin users. Aliment Pharmacol Ther. 2017;45:1542-1550. [PMID: 28449186 DOI: 10.1111/apt.14079] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 6.4] [Reference Citation Analysis]
341 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
342 Rizvi F, Khan M, Jabeen A, Siddiqui H, Choudhary MI. Studies on Isoniazid Derivatives through a Medicinal Chemistry Approach for the Identification of New Inhibitors of Urease and Inflammatory Markers. Sci Rep 2019;9:6738. [PMID: 31043636 DOI: 10.1038/s41598-019-43082-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
343 Koch CD, Gladwin MT, Freeman BA, Lundberg JO, Weitzberg E, Morris A. Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. Free Radic Biol Med 2017;105:48-67. [PMID: 27989792 DOI: 10.1016/j.freeradbiomed.2016.12.015] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
344 Min YW, Kang D, Shin JY, Kang M, Park JK, Lee KH, Lee JK, Lee KT, Rhee PL, Kim JJ, Guallar E, Cho J, Lee H. Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study. Aliment Pharmacol Ther. 2019;50:760-768. [PMID: 31448440 DOI: 10.1111/apt.15466] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
345 Furukawa M, Moriya K, Nakayama J, Inoue T, Momoda R, Kawaratani H, Namisaki T, Sato S, Douhara A, Kaji K, Kitade M, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Tanaka Y, Yoshiji H. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis.Hepatol Res. 2020;50:840-852. [PMID: 32346970 DOI: 10.1111/hepr.13509] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
346 Hattori S, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Yamamoto K, Ishikawa T, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Hirooka Y, Fujishiro M. The microbiome can predict mucosal healing in small intestine in patients with Crohn's disease. J Gastroenterol 2020;55:1138-49. [PMID: 33067682 DOI: 10.1007/s00535-020-01728-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
347 Martinsen TC, Fossmark R, Waldum HL. The Phylogeny and Biological Function of Gastric Juice-Microbiological Consequences of Removing Gastric Acid. Int J Mol Sci 2019;20:E6031. [PMID: 31795477 DOI: 10.3390/ijms20236031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
348 Lee SM, Kim N, Nam RH, Park JH, Choi SI, Park YT, Kim YR, Seok YJ, Shin CM, Lee DH. Gut microbiota and butyrate level changes associated with the long-term administration of proton pump inhibitors to old rats. Sci Rep 2019;9:6626. [PMID: 31036935 DOI: 10.1038/s41598-019-43112-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
349 Read E, Curtis MA, Neves JF. The role of oral bacteria in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:731-42. [PMID: 34400822 DOI: 10.1038/s41575-021-00488-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Taha AS. Vonoprazan, aspirin and NSAIDs: new era in acid inhibition and gastroprotection. Gut 2018;67:995-6. [PMID: 29208676 DOI: 10.1136/gutjnl-2017-315252] [Reference Citation Analysis]
351 Diao X. Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer. Thorac Cancer 2020;11:1763-4. [PMID: 32374445 DOI: 10.1111/1759-7714.13470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
352 Gracie DJ, Ford AC. The possible risks of proton pump inhibitors. Med J Aust 2016;205:292-3. [PMID: 27681962 DOI: 10.5694/mja16.00750] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
353 Kohi S, Macgregor-Das A, Dbouk M, Yoshida T, Chuidian M, Abe T, Borges M, Lennon AM, Shin EJ, Canto MI, Goggins M. Alterations in the Duodenal Fluid Microbiome of Patients With Pancreatic Cancer. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31519-6. [PMID: 33161160 DOI: 10.1016/j.cgh.2020.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
354 Kaur G, Behl T, Bungau S, Kumar A, Uddin MS, Mehta V, Zengin G, Mathew B, Shah MA, Arora S. Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson's Disease. Curr Neuropharmacol 2021;19:233-47. [PMID: 32504503 DOI: 10.2174/1570159X18666200606233050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
355 Lepczyńska M, Dzika E, Chen W, Lu CY. Influence of Proton Pump Inhibitors and Histamine Receptor 2 Antagonists on Blastocystis ST3 and Selected Microorganisms of Intestinal Microbiota In Vitro. Clin Transl Gastroenterol 2021;12:e00325. [PMID: 33835078 DOI: 10.14309/ctg.0000000000000325] [Reference Citation Analysis]
356 Kostrzewska M, Świdnicka-Siergiejko A, Olszańska D, Jurkowska G, Garley M, Ratajczak-Wrona W, Jabłońska E, Jamiołkowski J, Dabrowski A. The effect of omeprazole treatment on the gut microflora and neutrophil function. Clin Res Hepatol Gastroenterol 2017;41:575-84. [PMID: 28258834 DOI: 10.1016/j.clinre.2017.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
357 Ticinesi A, Milani C, Lauretani F, Nouvenne A, Mancabelli L, Lugli GA, Turroni F, Duranti S, Mangifesta M, Viappiani A, Ferrario C, Maggio M, Ventura M, Meschi T. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep 2017;7:11102. [PMID: 28894183 DOI: 10.1038/s41598-017-10734-y] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 16.6] [Reference Citation Analysis]
358 Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Target Oncol 2021. [PMID: 34894318 DOI: 10.1007/s11523-021-00861-y] [Reference Citation Analysis]
359 Di Pilato V, Freschi G, Ringressi MN, Pallecchi L, Rossolini GM, Bechi P. The esophageal microbiota in health and disease. Ann N Y Acad Sci. 2016;1381:21-33. [PMID: 27415419 DOI: 10.1111/nyas.13127] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
360 Choi DS, Seo SI, Shin WG, Park CH. Risk for Colorectal Neoplasia in Patients With Helicobacter pylori Infection: A Systematic Review and Meta-analysis. Clin Transl Gastroenterol 2020;11:e00127. [PMID: 32032128 DOI: 10.14309/ctg.0000000000000127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
361 Murata M, Sugimoto M, Otsuka T, Nishida A, Inatomi O, Bamba S, Andoh A. Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation. Helicobacter 2018;23. [DOI: 10.1111/hel.12543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
362 Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:l1580. [PMID: 31147311 DOI: 10.1136/bmj.l1580] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 21.3] [Reference Citation Analysis]
363 Villafuerte-Gálvez JA. Proton Pump Inhibitors and Incident Clostridioides difficile Infection: Beyond Controversy, Pragmatic Approaches Are Needed. Clin Infect Dis 2021;72:e1090-2. [PMID: 33320187 DOI: 10.1093/cid/ciaa1856] [Reference Citation Analysis]
364 Sáenz JB. Follow the Metaplasia: Characteristics and Oncogenic Implications of Metaplasia's Pattern of Spread Throughout the Stomach. Front Cell Dev Biol 2021;9:741574. [PMID: 34869328 DOI: 10.3389/fcell.2021.741574] [Reference Citation Analysis]
365 Frost F, Kacprowski T, Rühlemann M, Pietzner M, Bang C, Franke A, Nauck M, Völker U, Völzke H, Dörr M, Baumbach J, Sendler M, Schulz C, Mayerle J, Weiss FU, Homuth G, Lerch MM. Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function. Gut 2021;70:522-30. [PMID: 33168600 DOI: 10.1136/gutjnl-2020-322753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
366 Le Bastard Q, Al-Ghalith GA, Grégoire M, Chapelet G, Javaudin F, Dailly E, Batard E, Knights D, Montassier E. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment Pharmacol Ther 2018;47:332-45. [PMID: 29205415 DOI: 10.1111/apt.14451] [Cited by in Crossref: 94] [Cited by in F6Publishing: 86] [Article Influence: 18.8] [Reference Citation Analysis]
367 Gawałko M, Agbaedeng TA, Saljic A, Müller DN, Wilck N, Schnabel R, Penders J, Rienstra M, van Gelder I, Jespersen T, Schotten U, Crijns HJGM, Kalman JM, Sanders P, Nattel S, Dobrev D, Linz D. Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. Cardiovasc Res 2021:cvab292. [PMID: 34550344 DOI: 10.1093/cvr/cvab292] [Reference Citation Analysis]
368 Segregur D, Flanagan T, Mann J, Moir A, Karlsson EM, Hoch M, Carlile D, Sayah-jeanne S, Dressman J. Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes. Journal of Pharmaceutical Sciences 2019;108:3461-77. [DOI: 10.1016/j.xphs.2019.06.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
369 Li DK, Yan P, Abou-Samra AB, Chung RT, Butt AA. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES. Aliment Pharmacol Ther 2018;47:246-58. [PMID: 29105111 DOI: 10.1111/apt.14391] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
370 Kamo T, Akazawa H, Suda W, Saga-Kamo A, Shimizu Y, Yagi H, Liu Q, Nomura S, Naito AT, Takeda N, Harada M, Toko H, Kumagai H, Ikeda Y, Takimoto E, Suzuki JI, Honda K, Morita H, Hattori M, Komuro I. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One 2017;12:e0174099. [PMID: 28328981 DOI: 10.1371/journal.pone.0174099] [Cited by in Crossref: 89] [Cited by in F6Publishing: 71] [Article Influence: 17.8] [Reference Citation Analysis]
371 Shimizu K, Seiki I, Goto Y, Murata T. Measurement of the Intestinal pH in Mice under Various Conditions Reveals Alkalization Induced by Antibiotics. Antibiotics (Basel) 2021;10:180. [PMID: 33670214 DOI: 10.3390/antibiotics10020180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
372 Gutiérrez-Repiso C, Moreno-Indias I, Martín-Núñez GM, Ho-Plagaro A, Ocaña-Wilhelmi L, Fernández García D, Gonzalo Marín M, Moreno-Ruiz FJ, García-Fuentes E, Tinahones FJ. Influence of Factors Altering Gastric Microbiota on Bariatric Surgery Metabolic Outcomes. Microbiol Spectr 2021;:e0053521. [PMID: 34787463 DOI: 10.1128/Spectrum.00535-21] [Reference Citation Analysis]
373 Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Goldenberg SD, Williams HRT. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: Joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut. 2018;67:1920-1941. [PMID: 30154172 DOI: 10.1136/gutjnl-2018-316818] [Cited by in Crossref: 126] [Cited by in F6Publishing: 117] [Article Influence: 31.5] [Reference Citation Analysis]
374 Chawla BK, Cohen RE, Yerke LM. Association between proton pump inhibitors and periodontal disease severity. Clin Exp Dent Res 2021. [PMID: 34545705 DOI: 10.1002/cre2.495] [Reference Citation Analysis]
375 Lee KA, Shaw HM, Bataille V, Nathan P, Spector TD. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications. Eur J Cancer 2020;138:149-55. [PMID: 32889369 DOI: 10.1016/j.ejca.2020.07.026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
376 Collins S, Reid G. Distant Site Effects of Ingested Prebiotics. Nutrients 2016;8:E523. [PMID: 27571098 DOI: 10.3390/nu8090523] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
377 Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M, Albera C, Antoniou KM, Altinisik G, Bendstrup E, Bondue B, Borie R, Brown KK, Camus P, Castillo D, Collard HR, Cottin V, Crimi N, Ferrara G, Fischer A, Gauldie J, Geiser T, Guenther A, Hambly N, Hansell DM, Harari S, Jones MG, Keane M, Ley B, Maher TM, Molina-molina M, Palmucci S, Poletti V, Prasse A, Rottoli P, Spagnolo P, Sterclova M, Torrisi S, Tsitoura E, Vasakova M, Walsh SL, Wijsenbeek MS, Wuyts WA. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? The Lancet Respiratory Medicine 2017;5:591-8. [DOI: 10.1016/s2213-2600(17)30219-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 16] [Article Influence: 8.8] [Reference Citation Analysis]
378 Silveira ALM, Ferreira AVM, Teixeira MM. High-Fiber Diets in Gastrointestinal Tract Diseases. Dietary Interventions in Gastrointestinal Diseases. Elsevier; 2019. pp. 229-44. [DOI: 10.1016/b978-0-12-814468-8.00019-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
379 Hämäläinen I, Törnwall O, Simell B, Zatloukal K, Perola M, van Ommen GB. Role of Academic Biobanks in Public-Private Partnerships in the European Biobanking and BioMolecular Resources Research Infrastructure Community. Biopreserv Biobank 2019;17:46-51. [PMID: 30499696 DOI: 10.1089/bio.2018.0024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
380 Patel VC, Williams R. Antimicrobial resistance in chronic liver disease. Hepatol Int. 2020;14:24-34. [PMID: 31797303 DOI: 10.1007/s12072-019-10004-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
381 Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol 2021;45:101397. [PMID: 32224118 DOI: 10.1016/j.clinre.2020.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
382 Hov JR. Editorial: proton pump inhibition - microbial complications beyond dysbiosis. Aliment Pharmacol Ther 2019;50:962-3. [PMID: 31591776 DOI: 10.1111/apt.15495] [Reference Citation Analysis]
383 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
384 Thingholm LB, Rühlemann MC, Koch M, Fuqua B, Laucke G, Boehm R, Bang C, Franzosa EA, Hübenthal M, Rahnavard A, Frost F, Lloyd-Price J, Schirmer M, Lusis AJ, Vulpe CD, Lerch MM, Homuth G, Kacprowski T, Schmidt CO, Nöthlings U, Karlsen TH, Lieb W, Laudes M, Franke A, Huttenhower C. Obese Individuals with and without Type 2 Diabetes Show Different Gut Microbial Functional Capacity and Composition.Cell Host Microbe. 2019;26:252-264.e10. [PMID: 31399369 DOI: 10.1016/j.chom.2019.07.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 69] [Article Influence: 21.7] [Reference Citation Analysis]
385 Kamal H, Sadr-Azodi O, Engstrand L, Brusselaers N. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study. Hepatology 2021. [PMID: 34018229 DOI: 10.1002/hep.31914] [Reference Citation Analysis]
386 Yasutomi E, Hoshi N, Adachi S, Otsuka T, Kong L, Ku Y, Yamairi H, Inoue J, Ishida T, Watanabe D, Ooi M, Yoshida M, Tsukimi T, Fukuda S, Azuma T. Proton Pump Inhibitors Increase the Susceptibility of Mice to Oral Infection with Enteropathogenic Bacteria. Dig Dis Sci 2018;63:881-9. [DOI: 10.1007/s10620-017-4905-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
387 Li Y, Chen F, Xie Y, Yang Q, Luo H, Jia P, Shi Z, Wang S, Zheng X. Feiyangchangweiyan capsule protects against ulcerative colitis in mice by modulating the OSM/OSMR pathway and improving gut microbiota. Phytomedicine 2021;80:153372. [PMID: 33113505 DOI: 10.1016/j.phymed.2020.153372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
388 Fan L, Lee JH. Enteral feeding and the microbiome in critically ill children: a narrative review. Transl Pediatr 2021;10:2778-91. [PMID: 34765500 DOI: 10.21037/tp-20-349] [Reference Citation Analysis]
389 Doestzada M, Vila AV, Zhernakova A, Koonen DPY, Weersma RK, Touw DJ, Kuipers F, Wijmenga C, Fu J. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell 2018;9:432-45. [PMID: 29705929 DOI: 10.1007/s13238-018-0547-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
390 Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloi M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017;66:569-80. [PMID: 28087657 DOI: 10.1136/gutjnl-2016-313017] [Cited by in Crossref: 425] [Cited by in F6Publishing: 365] [Article Influence: 85.0] [Reference Citation Analysis]
391 Frost F, Kacprowski T, Rühlemann M, Bang C, Franke A, Zimmermann K, Nauck M, Völker U, Völzke H, Biffar R, Schulz C, Mayerle J, Weiss FU, Homuth G, Lerch MM. Helicobacter pylori infection associates with fecal microbiota composition and diversity.Sci Rep. 2019;9:20100. [PMID: 31882864 DOI: 10.1038/s41598-019-56631-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
392 Nishihara Y, Ogino H, Tanaka M, Ihara E, Fukaura K, Nishioka K, Chinen T, Tanaka Y, Nakayama J, Kang D, Ogawa Y. Mucosa-associated gut microbiota reflects clinical course of ulcerative colitis. Sci Rep 2021;11:13743. [PMID: 34215773 DOI: 10.1038/s41598-021-92870-0] [Reference Citation Analysis]
393 Fan C, Zhang S, Gong Z, Li X, Xiang B, Deng H, Zhou M, Li G, Li Y, Xiong W, Zeng Z, Li X. Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Sci China Life Sci 2021;64:534-47. [PMID: 32815067 DOI: 10.1007/s11427-019-1735-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
394 Samadi N, Heiden D, Klems M, Salzmann M, Rohrhofer J, Weidmann E, Koidl L, Jensen-Jarolim E, Untersmayr E. Gastric Enzyme Supplementation Inhibits Food Allergy in a BALB/c Mouse Model. Nutrients 2021;13:738. [PMID: 33652629 DOI: 10.3390/nu13030738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Cerri S, Taminiau B, de Lusancay AH, Lecoq L, Amory H, Daube G, Cesarini C. Effect of oral administration of omeprazole on the microbiota of the gastric glandular mucosa and feces of healthy horses. J Vet Intern Med 2020;34:2727-37. [PMID: 33063923 DOI: 10.1111/jvim.15937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
396 Salvadori M, Tsalouchos A. Microbiota, renal disease and renal transplantation. World J Transplant 2021; 11(3): 16-36 [PMID: 33816144 DOI: 10.5500/wjt.v11.i3.16] [Reference Citation Analysis]
397 Pasman EA, Ong B, Witmer CP, Nylund CM. Proton Pump Inhibitors in Children: the Good, the Bad, and the Ugly. Curr Allergy Asthma Rep 2020;20:39. [PMID: 32524278 DOI: 10.1007/s11882-020-00926-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
398 Seo SI, You SC, Park CH, Kim TJ, Ko YS, Kim Y, Yoo JJ, Kim J, Shin WG. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model. J Gastroenterol Hepatol 2020;35:1325-30. [PMID: 31970824 DOI: 10.1111/jgh.14983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
399 Stark CM, Susi A, Emerick J, Nylund CM. Antibiotic and acid-suppression medications during early childhood are associated with obesity. Gut. 2019;68:62-69. [PMID: 30377188 DOI: 10.1136/gutjnl-2017-314971] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
400 Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. Digestion. 2018;97:195-204. [PMID: 29316555 DOI: 10.1159/000481813] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 11.0] [Reference Citation Analysis]
401 Swarte JC, Douwes RM, Hu S, Vich Vila A, Eisenga MF, van Londen M, Gomes-Neto AW, Weersma RK, Harmsen HJM, Bakker SJL. Characteristics and Dysbiosis of the Gut Microbiome in Renal Transplant Recipients. J Clin Med. 2020;9. [PMID: 32024079 DOI: 10.3390/jcm9020386] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
402 Kim D, Hofstaedter CE, Zhao C, Mattei L, Tanes C, Clarke E, Lauder A, Sherrill-Mix S, Chehoud C, Kelsen J, Conrad M, Collman RG, Baldassano R, Bushman FD, Bittinger K. Optimizing methods and dodging pitfalls in microbiome research. Microbiome 2017;5:52. [PMID: 28476139 DOI: 10.1186/s40168-017-0267-5] [Cited by in Crossref: 235] [Cited by in F6Publishing: 218] [Article Influence: 47.0] [Reference Citation Analysis]
403 Tan Q, Orsso CE, Deehan EC, Kung JY, Tun HM, Wine E, Madsen KL, Zwaigenbaum L, Haqq AM. Probiotics, prebiotics, synbiotics, and fecal microbiota transplantation in the treatment of behavioral symptoms of autism spectrum disorder: A systematic review. Autism Res 2021;14:1820-36. [PMID: 34173726 DOI: 10.1002/aur.2560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
404 Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut 2020;69:1510-9. [PMID: 32409589 DOI: 10.1136/gutjnl-2019-320204] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 22.5] [Reference Citation Analysis]
405 Lin Y, Wu SH, Wang XH, Zhang W, Li BG, Liu WS. Associations of imbalance of intestinal flora with severity of disease, inflammatory factors, adiponectin, and vascular endothelial function of hypertension patients. Kaohsiung J Med Sci 2021. [PMID: 34672426 DOI: 10.1002/kjm2.12459] [Reference Citation Analysis]
406 Garg K, Kramer J, Eswaran S. Common Gastrointestinal Medications Implicated in Drug-Induced Liver Injury. Clin Liver Dis (Hoboken) 2021;18:184-8. [PMID: 34745575 DOI: 10.1002/cld.1110] [Reference Citation Analysis]
407 Walker GT, Yang G, Tsai JY, Rodriguez JL, English BC, Faber F, Souvannaseng L, Butler BP, Tsolis RM. Malaria parasite infection compromises colonization resistance to an enteric pathogen by reducing gastric acidity. Sci Adv 2021;7:eabd6232. [PMID: 34193410 DOI: 10.1126/sciadv.abd6232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, Deelen P, Vatanen T, Schirmer M, Smeekens SP. The effect of host genetics on the gut microbiome. Nat Genet. 2016;48:1407-1412. [PMID: 27694959 DOI: 10.1038/ng.3663] [Cited by in Crossref: 383] [Cited by in F6Publishing: 314] [Article Influence: 63.8] [Reference Citation Analysis]
409 He JW, Zhou XJ, Hou P, Wang YN, Gan T, Li Y, Liu Y, Liu LJ, Shi SF, Zhu L, Lv JC, Zhang H. Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A Nephropathy. Front Cell Infect Microbiol 2021;11:652837. [PMID: 33869084 DOI: 10.3389/fcimb.2021.652837] [Reference Citation Analysis]
410 Adolph TE, Grander C, Moschen AR, Tilg H. Liver–Microbiome Axis in Health and Disease. Trends in Immunology 2018;39:712-23. [DOI: 10.1016/j.it.2018.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 14.3] [Reference Citation Analysis]
411 Lee KA, Luong MK, Shaw H, Nathan P, Bataille V, Spector TD. The gut microbiome: what the oncologist ought to know. Br J Cancer 2021. [PMID: 34262150 DOI: 10.1038/s41416-021-01467-x] [Reference Citation Analysis]
412 Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, Albert ML, Powles T, Kok M, Herrera FG; imCORE working group of early career investigators. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol 2020;31:525-31. [PMID: 32115349 DOI: 10.1016/j.annonc.2020.01.006] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 28.5] [Reference Citation Analysis]
413 Wang X, Tang Q, Hou H, Zhang W, Li M, Chen D, Gu Y, Wang B, Hou J, Liu Y, Cao H. Gut Microbiota in NSAID Enteropathy: New Insights From Inside. Front Cell Infect Microbiol 2021;11:679396. [PMID: 34295835 DOI: 10.3389/fcimb.2021.679396] [Reference Citation Analysis]
414 Lanas-gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 2019;18:1043-53. [DOI: 10.1080/14740338.2019.1664470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
415 Nayak RR, Turnbaugh PJ. Mirror, mirror on the wall: which microbiomes will help heal them all? BMC Med. 2016;14:72. [PMID: 27146150 DOI: 10.1186/s12916-016-0622-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
416 van Olst N, Meiring S, de Brauw M, Bergman JJ, Nieuwdorp M, van der Peet DL, Gerdes VE. Small intestinal physiology relevant to bariatric and metabolic endoscopic therapies: Incretins, bile acid signaling, and gut microbiome. Techniques and Innovations in Gastrointestinal Endoscopy 2020;22:109-19. [DOI: 10.1016/j.tige.2020.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
417 Davies NK, O'Sullivan JM, Plank LD, Murphy R. Altered gut microbiome after bariatric surgery and its association with metabolic benefits: A systematic review. Surg Obes Relat Dis 2019;15:656-65. [PMID: 30824335 DOI: 10.1016/j.soard.2019.01.033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
418 Debédat J, Amouyal C, Aron-wisnewsky J, Clément K. Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome? Semin Immunopathol 2019;41:461-75. [DOI: 10.1007/s00281-019-00738-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
419 Hong S, Lee E, Shin J. Proton‐pump inhibitors and the risk of Clostridium difficile –associated diarrhea in high‐risk antibiotics users: A population‐based case‐crossover study. Pharmacoepidemiol Drug Saf 2019;28:479-88. [DOI: 10.1002/pds.4745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
420 Wellhöner F, Döscher N, Tergast TL, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Maasoumy B, Wedemeyer H, Cornberg M, Pieper DH, Heidrich B. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. Scand J Gastroenterol 2019;54:1033-41. [PMID: 31361979 DOI: 10.1080/00365521.2019.1647280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
421 Bartolomaeus H, McParland V, Wilck N. [Gut-heart axis : How gut bacteria influence cardiovascular diseases]. Herz 2020;45:134-41. [PMID: 32077981 DOI: 10.1007/s00059-020-04897-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
422 Roland BC, Lee D, Miller LS, Vegesna A, Yolken R, Severance E, Prandovszky E, Zheng XE, Mullin GE. Obesity increases the risk of small intestinal bacterial overgrowth (SIBO). Neurogastroenterol Motil 2018;30:e13199. [DOI: 10.1111/nmo.13199] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
423 Clos-Garcia M, Andrés-Marin N, Fernández-Eulate G, Abecia L, Lavín JL, van Liempd S, Cabrera D, Royo F, Valero A, Errazquin N, Vega MCG, Govillard L, Tackett MR, Tejada G, Gónzalez E, Anguita J, Bujanda L, Orcasitas AMC, Aransay AM, Maíz O, López de Munain A, Falcón-Pérez JM. Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia.EBioMedicine. 2019;46:499-511. [PMID: 31327695 DOI: 10.1016/j.ebiom.2019.07.031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 11.7] [Reference Citation Analysis]
424 Tantai XX, Yang LB, Wei ZC, Xiao CL, Chen LR, Wang JH, Liu N. Association of proton pump inhibitors with risk of hepatic encephalopathy in advanced liver disease: A meta-analysis. World J Gastroenterol 2019; 25(21): 2683-2698 [PMID: 31210719 DOI: 10.3748/wjg.v25.i21.2683] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
425 Verhaegh BP, de Vries F, Masclee AA, Keshavarzian A, de Boer A, Souverein PC, Pierik MJ, Jonkers DM. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016;43:1004-13. [PMID: 26956016 DOI: 10.1111/apt.13583] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 11.5] [Reference Citation Analysis]
426 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
427 Jun T, Ozbek U, Dharmapuri S, Hardy-Abeloos C, Zhu H, Lin JY, Personeni N, Pressiani T, Nishida N, Lee PC, Lee CJ, Hildebrand H, Nimkar N, Paul S, Fessas P, Naeem M, Bettinger D, Khan U, Saeed A, Huang YH, Kudo M, Rimassa L, Marron TU, Pinato DJ, Ang C. Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 2021;13:17588359211010937. [PMID: 33995594 DOI: 10.1177/17588359211010937] [Reference Citation Analysis]
428 Jensen ET, Bertoni AG, Crago OL, Hoffman KL, Wood AC, Arzumanyan Z, Lam LK, Roll K, Sandow K, Wu M, Rich SS, Rotter JI, Chen YI, Petrosino JF, Goodarzi MO. Rationale, design and baseline characteristics of the Microbiome and Insulin Longitudinal Evaluation Study (MILES). Diabetes Obes Metab 2020;22:1976-84. [PMID: 32687239 DOI: 10.1111/dom.14145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
429 Liu J, Lahousse L, Nivard MG, Bot M, Chen L, van Klinken JB, Thesing CS, Beekman M, van den Akker EB, Slieker RC, Waterham E, van der Kallen CJH, de Boer I, Li-Gao R, Vojinovic D, Amin N, Radjabzadeh D, Kraaij R, Alferink LJM, Murad SD, Uitterlinden AG, Willemsen G, Pool R, Milaneschi Y, van Heemst D, Suchiman HED, Rutters F, Elders PJM, Beulens JWJ, van der Heijden AAWA, van Greevenbroek MMJ, Arts ICW, Onderwater GLJ, van den Maagdenberg AMJM, Mook-Kanamori DO, Hankemeier T, Terwindt GM, Stehouwer CDA, Geleijnse JM, 't Hart LM, Slagboom PE, van Dijk KW, Zhernakova A, Fu J, Penninx BWJH, Boomsma DI, Demirkan A, Stricker BHC, van Duijn CM. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med 2020;26:110-7. [PMID: 31932804 DOI: 10.1038/s41591-019-0722-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
430 van der Meulen TA, Harmsen HJ, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A, Fu J, Wijmenga C, Weersma RK, de Leeuw K, Bootsma H, Spijkervet FK, Vissink A, Kroese FG. Shared gut, but distinct oral microbiota composition in primary Sjögren's syndrome and systemic lupus erythematosus. Journal of Autoimmunity 2019;97:77-87. [DOI: 10.1016/j.jaut.2018.10.009] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 18.3] [Reference Citation Analysis]
431 Brushett S, Sinha T, Reijneveld SA, de Kroon MLA, Zhernakova A. The Effects of Urbanization on the Infant Gut Microbiota and Health Outcomes. Front Pediatr 2020;8:408. [PMID: 32903831 DOI: 10.3389/fped.2020.00408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
432 Yu TC, Zhou YL, Fang JY. Oral pathogen in the pathogenesis of colorectal cancer. J Gastroenterol Hepatol 2021. [PMID: 34837266 DOI: 10.1111/jgh.15743] [Reference Citation Analysis]
433 Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, Tsuchiya S, Okayama T, Dohi O, Yoshida N, Kamada K, Ishikawa T, Handa O, Konishi H, Okuda K, Tsujimoto Y, Ohnogi H, Itoh Y. The influence of long-term use of proton pump inhibitors on the gut microbiota: An age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62:100-105. [PMID: 29371761 DOI: 10.3164/jcbn.17-78] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 10.6] [Reference Citation Analysis]
434 Davies N, O’sullivan JM, Plank LD, Murphy R. Gut Microbial Predictors of Type 2 Diabetes Remission Following Bariatric Surgery. OBES SURG 2020;30:3536-48. [DOI: 10.1007/s11695-020-04684-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
435 Avelar Rodriguez D, Ryan PM, Toro Monjaraz EM, Ramirez Mayans JA, Quigley EM. Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. Front Pediatr 2019;7:363. [PMID: 31552207 DOI: 10.3389/fped.2019.00363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
436 Figueroa Castro CE, Munoz-price LS. Advances in Infection Control for Clostridioides (Formerly Clostridium) difficile Infection. Curr Treat Options Infect Dis 2019;11:12-22. [DOI: 10.1007/s40506-019-0179-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
437 Cai R, Cheng C, Chen J, Xu X, Ding C, Gu B. Interactions of commensal and pathogenic microorganisms with the mucus layer in the colon. Gut Microbes 2020;11:680-90. [PMID: 32223365 DOI: 10.1080/19490976.2020.1735606] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
438 Lee JK, Merchant SA, Schneider JL, Jensen CD, Fireman BH, Quesenberry CP, Corley DA. Proton Pump Inhibitor Use and Risk of Gastric, Colorectal, Liver, and Pancreatic Cancers in a Community-Based Population. Am J Gastroenterol 2020;115:706-15. [DOI: 10.14309/ajg.0000000000000591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
439 Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore D, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Williams HR, Goldenberg SD. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. J Hosp Infect. 2018;100 Suppl 1:S1-S31. [PMID: 30173851 DOI: 10.1016/j.jhin.2018.07.037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
440 Hannachi N, Camoin-Jau L. Drug Response Diversity: A Hidden Bacterium? J Pers Med 2021;11:345. [PMID: 33922920 DOI: 10.3390/jpm11050345] [Reference Citation Analysis]
441 Kienesberger B, Obermüller B, Singer G, Mittl B, Grabherr R, Mayrhofer S, Heinl S, Stadlbauer V, Horvath A, Miekisch W, Fuchs P, Klymiuk I, Till H, Castellani C. (S)-Reutericyclin: Susceptibility Testing and In Vivo Effect on Murine Fecal Microbiome and Volatile Organic Compounds. Int J Mol Sci 2021;22:6424. [PMID: 34203988 DOI: 10.3390/ijms22126424] [Reference Citation Analysis]
442 Hatton GB, Madla CM, Rabbie SC, Basit AW. All disease begins in the gut: Influence of gastrointestinal disorders and surgery on oral drug performance. Int J Pharm 2018;548:408-22. [PMID: 29969711 DOI: 10.1016/j.ijpharm.2018.06.054] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
443 Xiong J, Wang Y, Chen G, Jin L. Proton pump inhibitors and the risk of gallbladder cancer: a hospital-based case-control study. Gut 2020;69:2265-7. [PMID: 32273291 DOI: 10.1136/gutjnl-2020-321052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
444 Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open 2018;8:e021869. [PMID: 29982219 DOI: 10.1136/bmjopen-2018-021869] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
445 Nieminen MT, Salaspuro M. Local Acetaldehyde-An Essential Role in Alcohol-Related Upper Gastrointestinal Tract Carcinogenesis. Cancers (Basel) 2018;10:E11. [PMID: 29303995 DOI: 10.3390/cancers10010011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
446 Walker AW, Flint HJ. Editorial: further evidence that proton pump inhibitors may impact on the gut microbiota. Aliment Pharmacol Ther 2016;43:1104-5. [PMID: 27072320 DOI: 10.1111/apt.13596] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
447 Maier L, Typas A. Systematically investigating the impact of medication on the gut microbiome. Curr Opin Microbiol 2017;39:128-35. [PMID: 29169088 DOI: 10.1016/j.mib.2017.11.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
448 Motta BM, Grander C, Gögele M, Foco L, Vukovic V, Melotti R, Fuchsberger C, De Grandi A, Cantaloni C, Picard A, Mascalzoni D, Rossini A, Pattaro C, Tilg H, Pramstaller PP. Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study. J Transl Med 2019;17:408. [PMID: 31801616 DOI: 10.1186/s12967-019-02130-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
449 Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP, France CP. Gut Reactions: Breaking Down Xenobiotic–Microbiome Interactions. Pharmacol Rev 2019;71:198-224. [DOI: 10.1124/pr.118.015768] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 33.7] [Reference Citation Analysis]
450 Hakozaki T, Okuma Y, Omori M, Hosomi Y. Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer. Oncol Lett 2019;17:2946-52. [PMID: 30854072 DOI: 10.3892/ol.2019.9899] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 6.7] [Reference Citation Analysis]
451 Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T; FHU ACRONIM. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 2021;157:474-84. [PMID: 34649118 DOI: 10.1016/j.ejca.2021.08.036] [Reference Citation Analysis]
452 Tranberg A, Samuelsson C, Klarin B. Disturbance in the oropharyngeal microbiota in relation to antibiotic and proton pump inhibitor medication and length of hospital stay. APMIS 2021;129:14-22. [PMID: 32981186 DOI: 10.1111/apm.13087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
453 Tomkovich S, Lesniak NA, Li Y, Bishop L, Fitzgerald MJ, Schloss PD. The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model. mSphere 2019;4:e00693-19. [PMID: 31748246 DOI: 10.1128/mSphere.00693-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
454 Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study. ESMO Open 2021;6:100090. [PMID: 33740735 DOI: 10.1016/j.esmoop.2021.100090] [Reference Citation Analysis]
455 Tanaka T, Matsuno Y, Torisu T, Shibata H, Hirano A, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Moriyama T, Esaki M, Kitazono T. Gastric microbiota in patients with Helicobacter pylori-negative gastric MALT lymphoma. Medicine (Baltimore) 2021;100:e27287. [PMID: 34559138 DOI: 10.1097/MD.0000000000027287] [Reference Citation Analysis]
456 Fisher L, Fisher A, Smith PN. Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review). J Clin Med 2020;9:E3253. [PMID: 33053671 DOI: 10.3390/jcm9103253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
457 Jabczyk M, Nowak J, Hudzik B, Zubelewicz-Szkodzińska B. Microbiota and Its Impact on the Immune System in COVID-19-A Narrative Review. J Clin Med 2021;10:4537. [PMID: 34640553 DOI: 10.3390/jcm10194537] [Reference Citation Analysis]
458 Cani PD. Human gut microbiome: hopes, threats and promises. Gut. 2018;67:1716-1725. [PMID: 29934437 DOI: 10.1136/gutjnl-2018-316723] [Cited by in Crossref: 447] [Cited by in F6Publishing: 405] [Article Influence: 111.8] [Reference Citation Analysis]
459 Brusselaers N. Prescribed Drugs and the Microbiome. Gastroenterol Clin North Am 2019;48:331-42. [PMID: 31383274 DOI: 10.1016/j.gtc.2019.04.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
460 Madison A, Kiecolt-Glaser JK. Stress, depression, diet, and the gut microbiota: human-bacteria interactions at the core of psychoneuroimmunology and nutrition. Curr Opin Behav Sci 2019;28:105-10. [PMID: 32395568 DOI: 10.1016/j.cobeha.2019.01.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
461 Mishiro T, Oka K, Kuroki Y, Takahashi M, Tatsumi K, Saitoh T, Tobita H, Ishimura N, Sato S, Ishihara S, Sekine J, Wada K, Kinoshita Y. Oral microbiome alterations of healthy volunteers with proton pump inhibitor. J Gastroenterol Hepatol. 2018;33:1059-1066. [PMID: 29105152 DOI: 10.1111/jgh.14040] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
462 Zheng YM, Chen XY, Cai JY, Yuan Y, Xie WR, Xu JT, Xia HHX, Zhang M, He XX, Wu LH. Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease. World J Gastroenterol 2021; 27(6): 513-522 [PMID: 33642825 DOI: 10.3748/wjg.v27.i6.513] [Reference Citation Analysis]
463 Chandrapalan S, Hee SW, Widlak MM, Farrugia A, Alam MT, Smith S, Arasaradnam RP. Performance of the faecal immunochemical test for the detection of colorectal neoplasms and the role of proton pump inhibitors in their diagnostic accuracy. Colorectal Dis 2021;23:1649-57. [PMID: 33991166 DOI: 10.1111/codi.15735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Sáenz JB, Mills JC. Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. Nat Rev Gastroenterol Hepatol 2018;15:257-73. [PMID: 29463907 DOI: 10.1038/nrgastro.2018.5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
465 van Kessel SP, El Aidy S. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease. Front Neurol 2019;10:1087. [PMID: 31681153 DOI: 10.3389/fneur.2019.01087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]